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Introduction  
Dry eye disease (DED) is a prevalent and multifactorial pathology of the ocular 
surface affecting 5-50% of the world’s population.1 The disease is characterized by 
a loss of homeostasis of the tear film and it may manifest with ocular symptoms 
such as dryness and burning.2,3 Tear hyperosmolarity and tear film instability 
constitute the core mechanisms in DED pathophysiology.4 Recently, neutrophil 
extracellular traps (NETs) have also been postulated to play a role in the 
pathogenesis of the disease.5,6 Artificial tears constitute the first-line therapy for 
mild dry eye.7 Nonetheless, most of these ophthalmic formulations in the market 
supplement only the aqueous phase of the tear film, providing primarily 
symptomatic relief. Furthermore, artificial tears have drawbacks such as short 
ocular residence time.8  
Objectives and Results 
Objective-1: Development of artificial tear formulations containing novel 
components, with suitable physicochemical properties, optimum tolerance, and 
extended ocular residence time. Liposomes were utilized to replenish the lipids of 
the tear film and bioadhesive and/or in situ gelling polymers (hydroxypropyl 
methylcellulose and/or gellan gum, respectively) to extend the ocular residence 
time of the formulations. In addition, antioxidants (vitamins A, C, and E), 
osmoprotectants (levocarnitine and trehalose), or antidessicants (trehalose) were 
incorporated into the formulations for their potential beneficial effects in DED 
treatment. The neutral to slightly alkaline pH (7.0–7.6), surface tension (44.6–48.7 
mN/m), viscosity (3.6–12.1 mPa.s), slight hypotonicity (222.7–272.7 mOsm/L), and 
liposome size (191.0–200.1 nm) exhibited by the formulations in the 
physicochemical characterization were considered suitable for topical ophthalmic 
administration. Formulations containing gellan gum produced viscoelastic gels 
with shear-thinning properties and suitable viscosities (2.8–3.0 mPa.s). In vivo 
tolerance studies (in rabbits) showed that the formulations resulted well 
tolerated. Objective-2: Development of novel tools to evaluate the efficacy of the 
artificial tear formulations. An in vivo dry eye model and an ex vivo dry eye model 
were developed. Dry eye was induced in rabbits with topical administration of the 
preservative benzalkonium chloride (BAK) at 0.1% for 15 days. Dry eye signs 
including corneal damage, goblet cell loss, and impairments in the conjunctival 
epithelium were observed in animals after the BAK treatment. Furthermore, a 
complete ex vivo porcine anterior eye model (Aston Biological Anterior Eye Model) 
was optimized by adjusting the irrigation frequency of the eyes with a tear 
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analogue. Objective-3: Efficacy studies of the novel artificial tear formulations. 
Preliminary studies. Preliminary efficacy studies of one of the novel formulations, 
composed of an in situ gelling polymer (gellan gum 0.25%), a bioadhesive polymer 
(hydroxypropyl methylcellulose 0.12%), osmoprotectants (levocarnitine 0.4% and 
trehalose 1.68%), an antioxidant (vitamin C 0.01%), electrolytes (sodium chloride 
0.05% and potassium chloride 0.05%), and borates (boric acid 0.84% and sodium 
tetraborate anhydrous 0.08%), were performed in the previously mentioned in 
vivo and ex vivo DED models, over a period of 21 days and 18 hours, respectively. 
In the in vivo model, the treatment with the artificial tear promoted significant 
improvements in the cornea and the conjunctiva at 7 days after continued 
treatment (significantly reduced fluorescein and cytological scores compared with 
baseline). In the ex vivo model, the formulation improved the ocular surface with 
two instillations after 18 hours, though the small sample size did not allow 
statistical analysis. Objective-4: Assessment of the effects of the novel artificial 
tear formulations on NET formation as a proof of concept. Excessive amounts and 
impaired clearance of NETs have been observed on the ocular surface of DED 
patients and linked with the pathogenesis of the disease.5,6 Effects of the novel 
artificial tear formulations on NET formation (NETosis) were assessed in 
neutrophils. The formulations did not increase NET formation in unstimulated 
neutrophils, demonstrating an optimal tolerance. Furthermore, in neutrophils 
stimulated with a NETosis inducing agent, all of the formulations reduced NET 
formation significantly. 
Conclusions 
1. All of the novel artificial tear formulations developed in this thesis, containing 
different combinations of liposomes (made up of phosphatidylcholine and 
cholesterol), a bioadhesive polymer (hydroxypropyl methylcellulose), an in situ 
gelling polymer (gellan gum), osmoprotectants (levocarnitine and trehalose), 
antioxidants (vitamins A, C, and E), and other formulation excipients (fructose, 
electrolytes, and borates) demonstrate suitable physicochemical properties for 
topical ophthalmic administration and are well tolerated in rabbits.  
2. Incorporation of gellan gum at 0.25% with electrolytes created artificial tears 
with in situ gelling properties, capable of producing viscoelastic gels that suggest 
an extended ocular residence time of the ophthalmic formulations. 
3. Twice-daily topical ophthalmic administration of the preservative benzalkonium 
chloride at 0.1% for 15 days induces significant alterations on the ocular surface 
of rabbits that are indicative of dry eye disease. The experimental dry eye model 
can be used as a platform to evaluate the efficacy of artificial tears.  
4. According to the preliminary efficacy studies performed in the in vivo dry eye 
model, the novel artificial tear containing the in situ gelling polymer gellan gum 
(0.25%), the bioadhesive polymer hydroxypropyl methylcellulose (0.12%), the 
osmoprotectants levocarnitine (0.4%) and trehalose (1.68%), the antioxidant 
vitamin C (0.01%), borates (boric acid 0.84% and sodium tetraborate anhydrous  
0.08%), and electrolytes (sodium chloride 0.05% and potassium chloride 0.05%) 
may be beneficial in DED treatment. 
Key words: dry eye, artificial tear, in situ gelling, bioadhesion, nanotechnology 
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Introducción  
La enfermedad de ojo seco (EOS) se considera una patología multifactorial que 
cursa con sequedad o quemazón de la superficie ocular con una prevalencia 
comprendida entre el 5 y el 50% de la población mundial.1–3 La hiperosmolaridad 
y la inestabilidad de la película lagrimal constituyen los mecanismos principales de 
la fisiopatología del EOS.4 Recientemente se ha postulado que las trampas 
extracelulares de neutrófilos (NET) están involucrados en la patogénesis de la 
enfermedad.5,6 Las lágrimas artificiales se utilizan con frecuencia como primera 
línea de tratamiento del EOS.7 Uno de los inconvenientes de estas formulaciones 
es el corto tiempo de residencia en la superficie ocular.8   
Objetivos y Resultados 
Objetivo-1: Desarrollo de formulaciones de lágrimas artificiales con componentes 
lipídicos y acuosos, que presenten propiedades fisicoquímicas adecuadas, 
tolerancia óptima y un tiempo de residencia prolonga do en la superficie ocular. 
Se han desarrollado nuevas formulaciones con componentes acuosos y lipídicos. 
Se formularon liposomas (compuestos por fosfatidilcolina y colesterol) con el 
objeto de reponer los lípidos de la película lacrimal. Se emplearon además 
polímeros bioadhesivos y/o gelificantes in situ (hidroxipropilmetilcelulosa (HPMC) 
y/o goma gelano respectivamente) para aumentar el tiempo de residencia ocular 
de las formulaciones. Además, se incluyeron antioxidantes (vitamina A, C y E), 
osmoprotectores (levocarnitina y trehalosa) o protectores frente a la desecación 
(trehalosa) por sus beneficios potenciales en el tratamiento del EOS. Las 
propiedades de las formulaciones: pH neutro o ligeramente alcalino (7,0–7,6); 
tensión superficial (44,6–48,7 mN/m), viscosidad (3,6–12,1 mPa.s), ligera 
hipotonicidad (222,7–272,7 mOsm/L) y distribución de tamaño (191,0–200,1 nm) 
resultaron adecuadas para su administración tópica oftálmica. Las formulaciones 
que contienen el polímero gelificante in situ goma gelano dieron lugar a geles 
viscoelásticos con propiedades pseudoplásticas y viscosidades adecuadas (2,8–3,0 
mPa.s). Las formulaciones presentaron una tolerancia óptima in vivo (conejos). 
Objetivo-2: Desarrollo de nuevas herramientas para evaluar la eficacia de las 
formulaciones de lágrimas artificiales. Se han desarrollado dos modelos de EOS (in 
vivo y ex vivo). En el modelo in vivo, se instiló cloruro de benzalconio (BAK) al 0,1% 
durante 15 días. Al final del estudio se observaron signos de sequedad ocular 
(daño en la córnea, pérdida de células caliciformes y alteraciones en el epitelio 
conjuntival). El modelo ex vivo se optimizó en colaboración con investigadores de 
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la Universidad de Aston, mediante el ajuste de la frecuencia de irrigación de los 
ojos con una lágrima artificial. Objetivo-3. Evaluación de la eficacia de las nuevas 
formulaciones de lágrimas artificiales. Estudios preliminares. La formulación 
conteniendo un polímero gelificante in situ (goma gelano 0,25%), un polímero 
bioadhesivo (HPMC 0,12%), osmoprotectores (levocarnitina 0,4% y trehalosa 
1,68%), un antioxidante (vitamina C 0,01%), electrolitos (cloruro de sodio 0,05% y 
cloruro de potasio 0,05%) y boratos (ácido bórico 0,84% y tetraborato de sodio 
anhidro 0,08%) se ensayó en los modelos de ojo seco in vivo y ex vivo 
anteriormente mencionados, durante 21 días y 18 horas, respectivamente. En el 
modelo in vivo, el tratamiento con la lágrima artificial generó una mejora 
significativa en la córnea y la conjuntiva tras 7 días de tratamiento. En el modelo 
ex vivo, el tratamiento mejoró la superficie ocular tras 18 horas, aunque el tamaño 
reducido de la muestra no permitió el análisis estadístico. Objetivo-4: Evaluación 
de los efectos de las nuevas formulaciones de lágrimas artificiales en la formación 
de NET como prueba de concepto. Los efectos de las nuevas formulaciones en la 
formación de NET (NETosis) se evaluaron en neutrófilos. Las lágrimas artificiales 
ensayadas no generaron un aumento en la formación de NET en neutrófilos no 
estimulados, demostrando así una tolerancia óptima. Además, en neutrófilos 
estimulados con un agente inductor de NETosis, todas las formulaciones 
redujeron, de forma significativa, la formación de NET en comparación con los 
neutrófilos estimulados que no recibieron ningún tratamiento. 
Conclusiones 
1. Las cinco formulaciones de lágrimas artificiales desarrolladas conteniendo 
liposomas (compuestos por fosfatidilcolina y colesterol), un polímero bioadhesivo 
(HPMC), un polímero gelificante in situ (goma gelano), agentes osmoprotectores 
(levocarnitina y trehalosa), agentes antioxidantes (vitaminas A, C y E) y otros 
excipientes como fructosa, electrolitos y boratos presentaron unas propiedades 
fisicoquímicas que resultan adecuadas para la administración tópica oftálmica. 
Además dichas formulaciones presentaron una tolerancia óptima in vivo (conejos).  
2. La incorporación de goma gelano (0,25%) generó la formación de lágrimas 
artificiales con propiedades gelificantes in situ, capaces de producir geles 
viscoelásticos que sugieren un tiempo de residencia ocular prolongado. 
3. La administración de BAK (0,1%) dos veces al día durante 15 días produjo 
alteraciones en la superficie ocular de conejos que son indicativas de EOS (daño 
corneal, reducción de la densidad de células caliciformes y alteraciones en el 
epitelio conjuntival). El modelo experimental de ojo seco desarrollado puede ser 
empleado como plataforma para evaluar la eficacia de lágrimas artificiales. 
4. De acuerdo con los estudios preliminares de eficacia en el modelo animal de 
EOS, la nueva lágrima artificial conteniendo goma gelano (0,25%), HPMC (0,12%), 
osmoprotectores (levocarnitina 0,4% y trehalosa 1,68%), vitamina C (0,01%), 
boratos (ácido bórico 0,84% y tetraborato de sodio anhidro 0,08%) y electrolitos 
(cloruro sódico 0,05% y cloruro potásico 0,05%), podría resultar beneficiosa en el 
tratamiento de EOS. 
Palabras clave: ojo seco, lágrimas artificiales, gelificación in situ, bioadhesión, 
nanotecnología 
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1.1. Tear film structure and function 
The lacrimal functional unit, composed of the ocular surface (cornea and 
conjunctiva), lacrimal glands, meibomian glands, and the connecting nerves, 
regulates tear homeostasis.9  
The tear film, overlying the cornea and the conjunctiva, is a dynamic structure that 
plays a crucial role in maintaining a healthy ocular surface. Conventionally, it has 
been considered to be composed of three separate layers: the outermost lipid 
layer, the middle aqueous layer, and the innermost mucus layer. The more 
recently proposed tear film structure suggests a different architecture, with an 
outer lipid layer and an underlying aqueous-mucin gel with a decreasing mucin 
gradient from epithelium to the outer surface. The two proposed structures of the 
tear film are shown in Figure 1.1. 
 
 
Figure 1.1. Schematic representations of the tear film structure. Left: The classical 
three-layered structure. Right: The more recently proposed tear film structure, with 
an outer lipid layer and an underlying aqueous gel with mucin content.  Adapted 
from Rolando et al.10 
 
Meibomian glands, located in the lid margins, secrete a lipid mixture called 
meibum. The meibum is spread over the ocular surface with blinking, providing 
the lipids of the tear film. The tear film lipid layer consists of polar and non-polar 
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lipids, including wax and cholesterol esters, triacylglycerol, free fatty acids, free 
cholesterol, and phospholipids.11,12 Butovich et al.12 identified also very long chain 
(O-acyl)-ω-hydroxy-fatty acids (OAHFAs) in human meibum. The authors 
suggested that OAHFAs, owing to their amphiphilic anionogenic nature, may be 
responsible for stabilization of the tear film lipid layer by creating an interface 
between the outermost non-polar lipids and the underlying aqueous phase. Figure 
1.2 illustrates a proposed model of the tear film, incorporating also intercalated 
proteins in the lipid layer. The primary functions of the lipid layer are reducing the 
evaporation of the underlying phase, maintaining tear film stability and a clear 
optical surface, and protecting the eye from microbes and foreign bodies by 
constituting a barrier.10,11 
 
 
Figure 1.2. A proposed model of the tear film. Adapted from Nichols et al.11 
 
The aqueous-mucin gel underneath the lipid layer of the tear film contains various 
components such as electrolytes, proteins, and mucins. The aqueous portion is 
secreted mainly by the lacrimal glands. Mucins lubricate the corneal and 
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conjunctival epithelial surfaces, stabilize the tear film by preventing the 
desiccation of the underlying epithelium, and provide an important barrier against 
pathogen penetrance.13–15 They provide a scaffolding and hold several anti-
microbial proteins such as immunoglobulins, lysozyme, transferrin, defensins, and 
members of the trefoil factor family at the epithelial surface.16 Mucins contribute 
to rheology, having low viscosity in blinking, where high shear rates are present, 
and higher viscosity in the open eye, due to their shear-thinning properties.17,18 
They are of particular importance because of their ability of forming gels19 and 
providing bioadhesion upon interacting with several polymers.  
Mucins can be divided into two classes: membrane-associated mucins, produced 
by corneal and conjunctival epithelia, and secreted mucins, secreted by goblet 
cells in the conjunctiva.13,14 Secreted mucins have two types: low molecular weight 
soluble mucins and high molecular weight gel-forming mucins.13,16 Soluble mucins 
are small monomers. Gel-forming mucins, able to form oligomers and generate 
macromolecules with a molecular weight up to 40 MDa, are involved in rheology 
and gel formation.16 Distribution of some of the membrane-associated mucins 
(MUC1, MUC4, MUC16) and the secreted mucin MUC5AC on the cornea and 
conjunctiva is illustrated in Figure 1.3. 
 
 
Figure 1.3. Illustration of the corneal and conjunctival epithelium demonstrating 
the distribution of the mucins. Membrane-associated mucins MUC1, MUC4, and 
MUC16 are located within apical cell membranes, and the secreted mucin MUC5AC 
within mucin packets in goblet cells. Adapted from Gipson.13 
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Tears can be classified as basal, reflex, emotional, and closed-eye tears.9 Tear 
drainage occurs through the nasolacrimal drainage system, via the flow of tears 
through upper and lower punctum, canaliculi, lacrimal sac, and nasolacrimal duct 
(Figure 1.4).  
 
 
Figure 1.4. Nasolacrimal drainage system. Adapted from Perry.20 
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1.2. Dry Eye Disease 
1.2.1. Definition and classification  
Dry eye disease (DED) is a highly prevalent health problem, affecting millions of 
people worldwide.21 It was defined by the National Eye Institute in 1995 as “a 
disorder of the tear film due to tear deficiency or excessive evaporation which 
causes damage to the interpalpebral ocular surface and is associated with 
symptoms of ocular discomfort”.22 As the understanding of the pathophysiology 
and mechanisms of DED advanced, the definition of the disease has evolved. The 
current internationally accepted definition of DED is the one produced by the 
Definition and Classification Subcommittee of the Tear Film & Ocular Surface 
(TFOS) Dry Eye WorkShop II (DEWS II) in 2017, which defines DED as “a 
multifactorial disease of the ocular surface characterized by a loss of homeostasis 
of the tear film, and accompanied by ocular symptoms, in which tear film 
instability and hyperosmolarity, ocular surface inflammation and damage, and 
neurosensory abnormalities play etiological roles”.2 The nomenclature for DED 
includes dry eye, dry eye syndrome, dry eye disorder, dysfunctional tear 
syndrome, and keratoconjunctivitis sicca, among others. 
Dry eye can be divided into two main categories: aqueous deficient dry eye (ADDE) 
and evaporative dry eye (EDE). Aqueous deficient dry eye arises from a reduced 
lacrimal tear secretion and can be further categorized into Sjogren syndrome dry 
eye and non-Sjogren syndrome dry eye. Sjogren syndrome is an autoimmune 
disease affecting lacrimal and salivary glands and resulting in dry eye and dry 
mouth. Evaporative dry eye, on the other hand, is due to excessive tear film 
evaporation, which can have intrinsic or extrinsic causes that may be lid-related or 
ocular surface-related.2,23 ADDE and EDE can also occur at the same time. The 
current classification of DED, produced by TFOS DEWS II in 2017, is illustrated in 
Figure 1.5. 
 30 
 
Figure 1.5. Classification of DED according to the 2017 TFOS DEWS II Report. 
Adapted from Craig et al.2 OSD: Ocular surface disease.  
 
Symptoms of DED may include dryness, burning, itching, discomfort, pain, 
redness, excessive tearing, gritty feeling, foreign body sensation, and eye fatigue.3 
DED is associated with a significant adverse impact on vision-related quality of life, 
causing difficulties in daily activities such as reading, driving, and computer use, as 
well as negatively affecting the patient’s psychological health.24,25 The impact of 
DED on quality of life has been reported to be comparable to the impact of 
moderate to severe angina.26  
The lack of a universally agreed standard diagnostic criteria for dry eye 
complicates the prevalence studies and the identification of risk factors. Patients’ 
symptoms evaluated subjectively via questionnaires and clinical signs assessed by 
diagnostic tests together may be used in the diagnosis of dry eye. Prevalence 
studies of dry eye present a range of 5-50%;1 with higher occurrence in the elderly, 
women, and Asian people. Increased age, female sex, Asian race, meibomian gland 
dysfunction, Sjogren syndrome, hormone replacement therapy, contact lens 
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wear, computer use, environmental factors (e.g. low humidity, pollution), and the 
use of certain medications (e.g. antidepressants, antihistamines) are identified as 
risk factors for DED.27 
1.2.2. Pathophysiology 
Regardless of the type and the etiologic cause of DED, two main mechanisms play 
an important role in the pathophysiology of the disease: tear hyperosmolarity and 
tear film instability. Tear hyperosmolarity may arise as a result of reduced aqueous 
flow (in ADDE) or increased tear film evaporation (in EDE). Tear hyperosmolarity 
triggers an inflammatory cascade by activating several signaling pathways in 
epithelial cells that result in the release of inflammatory mediators and proteases 
into tears. The release of these substances causes loss of epithelial and goblet cells 
and damage to epithelial glycocalyx, increasing tear film instability. Furthermore, 
tear film instability gives rise to tear film break-up and increased evaporation, 
which augments tear hyperosmolarity in turn, completing what is referred to as 
the “Vicious Circle” of DED and damaging the ocular surface (Figure 1.6).  
Tear film instability can develop secondary to tear hyperosmolarity (as a result of 
the events in the vicious circle) or due to several factors including meibomian 
gland dysfunction, topical preservative use, ocular allergy, and contact lens 
wear.23 Over the years, the understanding of the complex pathogenesis of DED 
has advanced and many etiological causes, that can enter the circle at different 
points, have been identified.  
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Figure 1.6. The core mechanisms in the vicious circle of DED. Adapted from Bron et 
al.4  
 
Elevated levels of extracellular DNA (eDNA) and neutrophil extracellular traps 
(NETs) in tears have recently been explored as contributing factors to the 
development of ocular surface damage and pathogenesis of DED. The epithelial 
cells of the ocular surface, as a part of their turnover, shed into the tear film and 
release eDNA. Neutrophils, as part of the immune defense, release nuclear 
contents into the extracellular space and form NETs for defense against microbes. 
Tear nucleases are responsible for the clearance of eDNA and NETs in tears. 
However, in the tear fluid of dry eye patients, increased levels of eDNA and NETs 
as well as a decreased nuclease activity were identified.5 Also, it has been shown 
that the formation of NETs is induced by hyperosmolarity.28  
1.3. Management and therapy of dry eye 
disease  
Due to the complex multifactorial nature and different severity levels of DED, 
several approaches have been developed for its management and therapy. 
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Current therapeutic approaches for DED include environmental and dietary and 
modifications, tear supplementation, tear conservation, tear stimulation, anti-
inflammatory therapy, treatment of lid-related conditions, and surgical 
approaches.29–35  
1.3.1. Environmental modifications  
“Environmental” factors of a patient such as the use of medications (preservative-
containing topical ophthalmic medications such as anti-glaucoma formulations, 
and systemic medications such as antidepressants, antihistamines, diuretics, beta-
blockers, and estrogen therapy), environmental conditions (e.g. low humidity, 
pollution, air conditioning), contact lens wear, and digital screen use are involved 
in DED and have been identified as risk factors.27 Modification of these 
environmental factors, or elimination when possible, is considered to be of 
importance in the management of DED.36 
1.3.2. Dietary modifications 
Essential fatty acids (EFAs) and antioxidants have been investigated for their 
potential beneficial effects in the management of DED.37,38  
EFAs are nutrients that cannot be synthetized in human body and must be 
obtained from the diet. They are required for several biological processes in the 
body and play an important role in proper physiological functions and good health. 
The EFAs can be grouped as omega-3 and omega-6 fatty acids; both groups are 
involved in the inflammatory processes. Omega-3 fatty acids play a role in the 
suppression of inflammatory processes, whereas omega-6 fatty acids generate 
certain proinflammatory mediators.36 Considering the role of inflammation in the 
pathogenesis of DED, increasing omega-3 intake, from diet and/or with oral 
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supplements, may be beneficial in the treatment of the disease.34 Sources of 
omega-3 fatty acids include fish oil, flaxseed oil, and soybean oil, among others. 
Oxidative stress, caused by an imbalance between the generation of reactive 
oxygen species (ROS) and the body’s antioxidant defense protecting against the 
harmful effects of ROS, can lead to tissue damage including ocular surface damage 
associated with DED.39 Therefore, dietary supplementation with antioxidants such 
as vitamin C, vitamin E, and alpha-lipoic acid may be beneficial in DED and are 
being investigated.40  
1.3.3. Tear supplementation 
Artificial tears and biological tear substitutes may be used to supplement the tear 
film. Artificial tears are considered the mainstay in the management of mild to 
moderate dry eye.7 They are usually available as over-the-counter eye drops or 
sprays. Artificial tear formulations can be water-based, which typically lubricate 
the eye and provide symptomatic relief, and more recently they can incorporate 
both aqueous and lipid components to replenish all layers of the tear film. Artificial 
tears are discussed in detail in Section 1.4.  
Autologous serum and allogeneic serum can be considered for the treatment of 
severe cases of dry eye. Serum is the liquid component of blood, free of blood cells 
and clotting factors. It is referred to as “autologous” when obtained from the 
patient’s own blood, and “allogeneic” when obtained from a donor’s blood. 
Recently, the use of autologous serum in dry eye has gained interest due to its 
advantage of containing substances found in tears that are important for the 
ocular surface, including vitamins, growth factors, immunoglobulins, and 
fibronectin, among other proteins and nutrients.41–43 A number of studies have 
investigated the clinical efficacy of autologous serum in DED patients and obtained 
positive results, among which are improvements in symptoms, tear break-up time 
(TBUT), Schirmer scores, and fluorescein staining, as well as increased goblet cell 
 35 
density.44–52 Drawbacks of autologous serum include regulatory issues regarding 
its production, stability issues over storage, and high cost. In patients with certain 
health conditions such as systemic inflammation or chronic anemia, in the elderly, 
or when autologous serum is not available for any other reason, the use of 
allogeneic serum may be an option; however, a potential risk of antigenicity 
exists.36,53  
1.3.4. Tear conservation 
Tear retention on the ocular surface may be beneficial in dry eye, particularly in 
aqueous deficient dry eye. Tear conservation approaches include punctal 
occlusion, use of moisture chamber spectacles, and therapeutic contact lens wear. 
Punctal occlusion involves blocking the lacrimal drainage by occluding either one 
or both of the puncta to increase tear retention on the ocular surface (Figure 1.7). 
Punctal occlusion can be temporary, by the insertion of absorbable punctal plugs 
(e.g. collagen-based); semi-permanent, by the insertion of non-absorbable plugs 
(e.g. silicone-based); and permanent, by surgical procedures. Collagen and silicon 
based punctal plugs have been shown to improve signs and symptoms of DED in 
clinical studies,54–60 though the evidence is limited and further studies are needed. 
It is important to mention that punctal plugs may have complications and cause 
adverse effects, including spontaneous plug loss or plus migration, epiphora (tear 
overflow), eye irritation, and foreign body sensation.61–64  
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Figure 1.7. Punctal occlusion with absorbable and non-absorbable plugs. Adapted 
from Calonge.30  
 
Moisture chamber spectacles are special glasses enclosing the eyes in order to 
shield them against the desiccating conditions of the environment such as wind, 
air conditioning, and dryness. By enclosing the ocular area, they also create a 
humid environment. As a result, moisture chamber spectacles provide retention 
of tears on the ocular surface and reduce tear evaporation.30 Therapeutic contact 
lenses, also referred to as bandage contact lenses, are also being explored for their 
potential use for tear retention. 
1.3.5. Tear stimulation  
Therapeutic agents called secretagogues may induce mucous and/or aqueous 
secretion and may be beneficial in DED. Diquafosol tetrasodium and rebamipide 
are examples of topically administered secretagogues. Both active substances are 
approved in Japan for the treatment of DED. Diquafasol tetrasodium induces 
aqueous and mucin secretion65,66 and rebamipide stimulates mucin secretion.67 
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The cholinergic agonists pilocarpine and cevimeline are orally administered 
secretagogues available for DED associated with Sjogren syndrome.36 
1.3.6. Anti-inflammatory therapy 
As mentioned in the pathophysiology of DED, inflammation plays an important 
role in the pathogenesis of both aqueous deficient and evaporative dry eye and 
may lead to ocular surface damage. Anti-inflammatory drug substances, such as 
cyclosporine, corticosteroids, and tetracyclines, can be considered for the therapy 
and management of the disease. 
Cyclosporine A, an immunosuppressant drug having anti-inflammatory effects, 
has gained significant interest in the treatment of DED. Topical cyclosporine A has 
been shown to improve dry eye signs (including tear film break-up time, Schirmer 
score, and corneal staining) and symptoms in DED patients and was evaluated as 
safe.68–70 Cyclosporine A has been commercialized as a topical ophthalmic 
emulsion at the concentration of 0.05% (Restasis; approved in 2003 by the Food 
and Drug Administration in the United States) and more recently as an 
unpreserved novel cationic nanoemulsion at the concentration of 0.1% (Ikervis; 
approved in 2015 by the European Medicines Agency in Europe).   
1.3.7. Treatment of lid-related conditions 
Meibomian gland dysfunction (MGD) is one of the major causes of evaporative dry 
eye that may present with insufficient lipid production and lipid supplement to the 
tear film.11 The condition results in reduced thickness and impairment of the tear 
film lipid layer, with a consequent tear film instability and elevated tear 
evaporation.71 The approaches for the treatment of MGD associated dry eye 
include replenishing the tear film lipids with the use of lipid-containing artificial 
tears and lubricants, heat therapy for the liquefaction of thick meibomian gland 
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secretions clogging the glands and for enhancing the flow of lipids to the ocular 
surface (e.g. warm compression devices and eye masks), and physical treatments 
(e.g. applying force, thermal pulsation treatment such as LipiFlow, intense pulsed 
light therapy).11,72,73  
Blepharitis is the inflammation of the eyelids that may arise as a result of bacterial 
overgrowth or mite infestation (e.g. Demodex) and can be associated with MGD.74 
Management and treatment approaches include maintaining an optimum lid 
hygiene (by lid wipes, scrubs, solutions), the use of topical antibiotics against 
bacterial overgrowth and tea tree oil against Demodex infestation, and in-office 
treatments.75,76 Among in-office treatments are electromechanical lid margin 
debridement to remove bacteria, mites, and biofilm from the eyelids (e.g. BlephEx 
treatment), thermal pulsation treatment, and intense pulsed light therapy.77  
1.3.8. Surgical approaches 
In cases of severe DED not responsive to other treatment approaches, surgical 
procedures can be considered. These procedures include tarsorraphy (partial or 
total closure of eyelids with sutures), salivary gland transplantation, amniotic 
membrane grafts, and lid corrections for patients with eyelid abnormalities, 
among others.36 
1.3.9. Choice of the treatment 
The type and the severity of DED should be considered when choosing the 
therapeutic approach for the disease. The Management and Therapy 
Subcommittee of 2007 TFOS DEWS29 reviewed the Dry Eye Preferred Practice 
Patterns of the American Academy of Ophthalmology and the International Task 
Force Delphi Panel on DED treatment and recommended different treatments 
based on the severity level of the disease. 2017 TFOS DEWS II Management and 
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Therapy Subcommittee proposed a staged management algorithm for DED (Figure 
1.8) and an updated version of treatment recommendations for different steps of 
the disease.36 The proposed treatment recommendations for each step, based on 
the staged management algorithm, are indicated in Table 1.1.36  
 
 
Figure 1.8. Staged management algorithm for DED proposed by 2017 TFOS DEWS 
II. Adapted from Jones et al.36  
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Table 1.1. Treatment recommendations for DED proposed by the Management and 
Therapy Subcommittee of 2017 TFOS DEWS II. Adapted from Jones et al.36 MGD: 
Meibomian gland dysfunction. 
  
Step 1
• Education
• Environmental and dietary modifications
• Identification and modification/elimination of offending medications
• Ocular lubricants
• Lid hygiene and warm compresses 
Step 2
• Non-preserved ocular lubricants
• Tea tree oil treatment for Demodex (if present)
• Tear conservation
• Overnight treatments (e.g. ointments, moisture chamber devices)
• In-office, physical heating and expression of the meibomian glands 
• In-office intense pulsed light therapy for MGD 
• Prescription drugs (e.g. topical secretagogues, topical corticosteroids)
Step 3
• Oral secretogogues 
• Autologous or allogeneic serum eye drops
• Therapeutic contact lenses 
Step 4
• Topical corticosteroids for longer duration
• Amniotic membrane grafts
• Surgical punctal occlusion
• Other surgical approaches (e.g. tarsorraphy, salivary gland 
transplantation)
If above options are inadequate, consider: 
 
If above options are inadequate, consider: 
 
If above options are inadequate, consider: 
ddddddd 
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1.4. Artificial tears 
Artificial tears may be formulated with a broad range of components. While the 
conventional formulations usually employ polymers with or without electrolytes 
and buffering agents, novel components and strategies are being developed to 
enhance the therapeutic efficacy of artificial tears. The key physicochemical 
aspects of artificial tears, main components of the conventional formulations as 
well as novel components and recent approaches, are discussed below.      
1.4.1. Physicochemical properties of artificial tears 
1.4.1.1. pH  
Tear pH plays an essential role in the normal cellular function on the ocular 
surface. Although a relatively broad human tear pH range, spanning from 5.2 to 
8.6, was historically reported in literature,78 more recent studies with more 
advanced measuring techniques have narrowed this range and reported a neutral 
to slightly alkaline human tear pH. Abelson et al.79 used a direct measurement 
technique, employing a microcombination glass pH probe to measure the pH of 
the tear fluid in the inferior cul-de-sac of humans, and established a pH range of 
6.5–7.6, with a mean pH value of 7.0. In another study, Yamada et al.80 measured 
the pH of the tear film of humans in vivo, using a pH-sensitive fluorescent dye, and 
reported a mean pH value of 7.5.  
Tear pH varies among individuals, depending on factors such as age and sex.81 It 
may also vary for a given individual throughout the day. During the day, a rise in 
tear pH, called alkaline shift, is observed.78,81 Nevertheless, the pH of the tear film 
and the ocular surface is maintained relatively stable under normal conditions. 
This is attributed to the well known chemical buffering capacity of tears, due to 
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the bicarbonate system, phosphates, ammonium, and proteins in their 
composition,82,83 as well as the tear turnover.84  
The overall buffering action of tears is of particular importance in neutralizing 
topical ophthalmic formulations and preventing them from causing discomfort 
upon instillation.84 Ophthalmic solutions with a pH out of the range 6.6-9.0 are 
likely to cause ocular discomfort and damage.84 Consequently, when formulating 
an artificial tear, the pH and the buffer systems to be used should receive special 
attention. An ideal artificial tear formulation should have neutral to slightly 
alkaline pH.  
1.4.1.2. Surface tension 
Surface tension of tears plays a very important role in the proper formation and 
stability of the tear film.85 Tear components such as lipids and proteins contribute 
to decrease surface tension, which is reported to be in the range of 40-46 
milliNewtons/meter (mN/m) in healthy state.86,87 Tear film stability has been 
demonstrated to decrease as the surface tension of the tear fluid increases,88 
emphasizing the importance of maintaining the physiological range. 
The surface tension of a topical ophthalmic formulation affects its interaction with 
the tear film and spreading ability on the ocular surface.89 Poor spreading may 
cause tear film instability and ocular discomfort. It may also induce blinking and 
lacrimation,90 causing formulations to wash out faster. Ophthalmic formulations 
with relatively low surface tension are expected to show better wetting 
properties. However, it was demonstrated that the instillation of an eye drop with 
a very low surface tension value (23 mN/m) resulted in the formation of a non-
homogenous film over the ocular surface.91 It was shown in another study that an 
artificial tear formulation with a surface tension value within the physiological 
range of tears (44 mN/m) presented better spreading ability and extended ocular 
residence time when compared with other two eye drops with higher surface 
tension values.92  
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Despite the advantages of having a surface tension value close to the values 
presented in tears, this is not the case for many commercialized formulations. Han 
et al.89 measured the surface tension of 7 ophthalmic formulations indicated for 
dry eye and reported that all of them had surface tension values that are higher 
than the surface tension of tears. In another study, Grgurević et al.90 determined 
the surface tension of 18 commercially available eye drops to evaluate their 
compatibility with the tear film in terms of surface tension. The authors reported 
that only 17% of the tested eye drops had a surface tension value within the range 
of 40–46 mN/m. The authors studied also the individual surface activity of some 
of the most commonly used ophthalmic excipients, including a number of 
thickening agents, solubilizing agents, and preservatives. They concluded that 
each of the ingredients of an ophthalmic formulation can influence its surface 
tension. Among the tested thickening agents, hydroxypropyl methylcellulose was 
the most effective in lowering the surface tension. 
In light of the afore-mentioned studies, it can be concluded that in the design of 
artificial tear formulations, it is important to take into consideration the surface 
active properties of the ingredients and prepare an artificial tear with a surface 
tension value within or near the physiological range of natural tears. 
1.4.1.3. Viscosity 
Natural tears show non-Newtonian shear-thinning behavior, with low viscosity at 
high shear rates to prevent damage to epithelial surfaces during blinking, and a 
higher viscosity in the open eye, to resist drainage and tear film break-up.17 The 
physiological range of the viscosity of natural tears is reported to be 1.0-8.3 
millipascal seconds (mPa.s).17,93 
It has been demonstrated that the eye drops that incorporate viscosity agents 
have prolonged residence time on the ocular surface.8,94 Polymeric systems are 
employed in artificial tears as viscosity enhancers. Ideally, the viscosity of an 
artificial tear should be within or near the physiological range for those that follow 
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Newtonian behavior. For artificial tears with non-Newtonian behavior, on the 
other hand, a dynamic viscosity within or near the aforementioned range would 
be desired. If the viscosity of an artificial tear is very high, it may cause blurred 
vision and irritation when instilled. 
1.4.1.4. Osmolarity 
Tear hyperosmolarity occurs both in aqueous deficient and evaporative dry eye, 
due to low aqueous tear flow and excessive tear film evaporation, respectively. 
Tear hyperosmolarity activates an inflammatory cascade and causes epithelial 
damage, leading to tear film instability.23  
In a multicenter study involving 10 centers and 314 subjects, the average tear 
osmolarity for normal subjects was found to be 300.8 milliosmoles/liter (mOsm/L), 
whereas subjects with mild to moderate dry eye and severe dry eye had tear 
osmolarity values of 315.5 mOsm/L and 336.7 mOsm/L, respectively.95 The 
authors found the most sensitive threshold between healthy and mild to 
moderate dry eye subjects to be 308 mOsm/L. In another study, Jacobi et al.96 
obtained consistent findings with Lemp et al.95 and suggested that a cutoff value 
of 308 mOsm/L would better identify the whole dry eye population, in comparison 
with the higher cutoff values previously described in the literature.  
Considering the increased tear osmolarity in DED patients, artificial tears should 
ideally be slightly hypotonic or isotonic, and incorporate compatible solutes called 
osmoprotectants.  
1.4.2. Conventional artificial tears: Main components 
Conventional artificial tears are typically water-based topical ophthalmic 
formulations incorporating one or a combination of polymers, electrolytes, 
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buffering agents, and preservatives. These formulations typically supplement the 
aqueous layer of the tear film and provide symptomatic relief.  
1.4.2.1. Polymers 
Polymers are widely used in artificial tears as viscosity agents and lubricants. They 
can be of natural, synthetic, or semi-synthetic origin. Among the most commonly 
used polymers in artificial tears are hyaluronic acid, cellulose derivatives, and 
synthetic polymers.97,98  
1.4.2.1.1. Hyaluronic acid 
Hyaluronic acid (HA; also referred to as hyaluronan) is a widely investigated 
polymer that has found applications in many topical dry eye formulations in the 
form of sodium hyaluronate. It is a naturally occurring linear polysaccharide with 
repeating disaccharide units composed of D-glucuronic acid and N-acetyl-D-
glucosamine. The polymer is an essential component of the extracellular matrix 
and found in all connective tissues (synovial fluids, vitreous humor, cartilage), 
where it displays a structural and rheological function, maintaining the 
viscoelasticity of liquid connective tissues.99 
 
 
Figure 1.9. Chemical structure of hyaluronic acid. 
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HA has several benefits which make it a desired polymer for topical dry eye 
formulations; it is biocompatible, biodegradable, non-toxic, and has a remarkable 
water-binding capacity.100 The polymer has shear-thinning properties; its viscosity 
changes with changing shear conditions.101 When the eye is open, it is highly coiled 
and viscous, therefore resists drainage, protects and hydrates the epithelium. 
During blinking, it uncoils due to lid friction and pressure and has reduced 
viscosity, providing smooth blinking.  
1.4.2.1.2. Cellulose derivatives  
Cellulose is a naturally occurring linear polysaccharide with a repeat unit of two D-
glucose molecules covalently linked via -(1→4) glycosidic bond. Cellulose 
derivatives carboxymethyl cellulose (CMC) and hydroxypropyl methylcellulose 
(HPMC) have found many applications in pharmaceutical industry including 
artificial tear formulations.  
 
 
 
Figure 1.10. Chemical structure of cellulose. 
 
CMC, also referred to as carmellose, is a polyanionic polysaccharide usually 
employed in the form of sodium CMC. HPMC, also referred to as hypromellose, is 
a nonionic viscoelastic polymer. Both macromolecules have been evaluated as 
having bioadhesive properties.102 Bioadhesion indicates the attachment of a 
substance to a specific biological site. When the biological site is covered by mucus 
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and an interaction occurs, it can be referred to as mucoadhesion.102 Bioadhesive, 
or mucoadhesive polymers, interact with the mucins of the tear film and provide 
a prolonged residence time of the formulation on the ocular surface. HPMC was 
also reported to possess antioxidant properties, protecting the ocular surface.103 
1.4.2.1.3. Synthetic polymers 
Synthetic polymers pose certain advantages over the natural ones such as very 
high reproducibility and the possibility of tailoring to obtain a range of desired 
properties.104 Among the most commonly used synthetic polymers in artificial 
tears are the acrylic polymer polyacrylic acid (PAA), the vinyl derivative polyvinyl 
alcohol (PVA), the polyol compound propylene glycol, and the polyether 
compound polyethylene glycol (PEG). Table 1.2 lists some of the most commonly 
used polymers in artificial tears. 
 
Origin Polymer Group 
Natural HA Polysaccharide 
Semisynthetic 
HPMC Cellulose derivative 
(polysaccharide derivative) 
CMC Cellulose derivative 
(polysaccharide derivative) 
Synthetic 
PAA Acrylic polymer 
PVA Vinyl derivative 
Propylene glycol Polyol compound 
PEG Polyether compound 
Table 1.2. Commonly used polymers in artificial tears. HA: hyaluronic acid, HPMC: 
hydroxypropyl methylcellulose, CMC: carboxymethyl cellulose, PAA: polyacrylic acid, 
PVA: polyvinyl alcohol, PEG: polyethylene glycol.  
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1.4.2.2. Electrolytes 
Tear film contains several electrolytes including sodium, potassium, calcium, 
magnesium, chloride, bicarbonate, and phosphate.9 The electrolytes contribute to 
the osmolarity of the tear film and are involved in maintaining the homeostasis of 
the ocular surface. Some of the commercially available artificial tears (e.g. Artelac 
Rebalance, Bion Tears, Murine Tears, TheraTears) offer electrolytes in their 
formulations. The electrolyte salts incorporated into such formulations include 
sodium chloride, calcium chloride, magnesium chloride, potassium chloride, zinc 
chloride, sodium bicarbonate, and sodium phosphate, among others. 
1.4.2.3. Buffering agents  
Several buffer systems are employed in artificial tears as excipients to adjust and 
maintain the pH, with the aim of preventing irritation upon topical ophthalmic 
administration. Such buffering agents include boric acid, acetic acid, borates, 
phosphates, citrate, and sodium bicarbonate, among others.105 
In 2012, upon encountering cases of corneal calcification in patients using 
phosphate-containing eye drops, the European Medicines Agency (EMA) 
evaluated the utilization of phosphate as buffer in medicinal eye drops.106 The 
Committee for Medicinal Products for Human Use (CMPH) of the EMA stated that 
corneal calcification may arise from the use of phosphate-containing eye drops in 
patients with significant corneal damage in very rare cases, identifing the risk as 
very low. The Committee suggested that it should be included among the possible 
side effects in the product information.  
1.4.2.4. Preservatives  
Preservatives have been employed in artificial tear formulations in order to 
prevent microbial growth in multi-dose containers. Quaternary ammoniums (e.g. 
benzalkonium chloride, cetrimide), alcohols (e.g. chlorobutanol), mercurial 
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derivatives (e.g. thiomersal), amidines (e.g. polyhexamethylene biguanide), and 
parabens (e.g. methylparaben) are among the traditionally used preservatives in 
topical ophthalmic formulations.  
Frequent and long-term exposure to preservatives can result in toxicity and 
damage to ocular surface. The most commonly used preservative in artificial tears 
is the quaternary ammonium compound benzalkonium chloride (BAK), which has 
long been associated with tear film instability and ocular cell damage. In vitro 
studies have shown that BAK can be cytotoxic for corneal and conjunctival 
epithelial cells at concentrations used in artificial tears (0.01%–0.02%).107,108  
While the preservative-free unit dose artificial tears remain an alternative to the 
preserved multi-dose artificial tears, they generally have a higher cost and they 
may not be available for every brand. Consequently, several strategies have been 
developed to overcome the toxicity issue due to the use of preservatives in multi-
dose artificial tears. These strategies include the use of newer preservatives with 
reduced harmful effects on the ocular surface (e.g. Polyquad), the use of 
“disappearing” preservatives (also referred to as “vanishing” or “soft” 
preservatives), the use of ionic buffers as preservative (e.g. SofZia; contains 
borate, sorbitol, propylene glycol, and zinc), and the application of special 
antimicrobial dispenser systems in product packaging. 
The disappearing preservatives are converted to non-toxic compounds upon 
administration. The disappearing preservatives include sodium perborate 
(GenAqua), stabilized oxychloro complex (Purite, OcuPure), and stabilized 
chlorite peroxide (Oxyd). The disappearing preservatives and their mode of 
disappearance are collected in Table 1.3.   
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Preservative Commercial 
name(s) 
Mode of disappearance 
Sodium perborate GenAqua Converted to water, oxygen, and 
hydrogen peroxide upon contact with 
the tear film 
Stabilized oxychloro complex Purite, 
OcuPure 
Degraded to sodium and chloride ions, 
water, and oxygen upon exposure to 
light 
Stabilized chlorite peroxide Oxyd Dissipates to water, oxygen and 
sodium chloride on the ocular surface  
Table 1.3. Disappearing preservatives used in artificial tears. 
 
Another alternative for non-preserved formulations in multi-dose containers is the 
use of special antimicrobial systems in packaging, such as the ABAK system and 
the COMOD system. The ABAK system has a dispenser with an antibacterial 
filter, while the COMOD system is an airless system that eliminates the contact 
of bacteria with the solution inside the bottle.  
1.4.3. Novel artificial tears: Novel components, 
technologies, and approaches 
1.4.3.1. Combination of lipid and aqueous components 
As previously described, tear film is composed of a lipid layer and an underlying 
aqueous-mucin gel (Section 1.1). The thickness of the lipid layer, as well as the 
quality of lipids, is very important in maintaining optimal properties of the 
lipophilic structure, which in turn reduces the evaporation of the underlying 
aqueous phase and plays a very crucial role in maintaining the tear film stability. 
In dry eye, particularly in evaporative dry eye associated with MGD, the lipid layer 
of the tear film is compromised, resulting in increased tear evaporation leading to 
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hyperosmolarity and tear film instability. Therefore, it is of great importance to 
replenish both the aqueous-mucin and lipid layers of the tear film. However, 
Conventional water-based artificial tears replace only the aqueous layer of the 
tear film and not the lipid layer. Lipid-only ocular lubricants for dry eye are 
available in the form of ointments or gels; however, due to the fact that they are 
very viscous and may cause blurred vision, they have found application mainly as 
night time dry eye products.  
Over the past years, combination of lipid and aqueous components with the aim 
of obtaining artificial tear formulations that more closely resemble natural tears 
and replenish both the lipid and the aqueous-mucin layer of the tear film has 
gained a lot of interest. A number of lipid-containing artificial tears are 
commercially available and such formulations are increasing in number. The 
majority of lipid-containing artificial tears are formulated in the form of emulsions, 
incorporating lipids such as mineral oil, castor oil, triglycerides, and 
phospholipids.109,110 Recently, lipid sprays have also gained interest.111–113 Several 
clinical studies evaluated the effects of lipid-containing artificial tears. Among the 
observed outcomes were increased lipid layer thickness, enhanced tear film 
stability, improved lipid layer structure, reduced tear evaporation, improvement 
in dry eye symptoms, and improvement in ocular surface healing and meibomian 
gland functionality.114–123 
1.4.3.2. Antioxidants 
An imbalance between the production and elimination of ROS can lead to elevated 
ROS levels and oxidative stress, which may have damaging effects.39 In dry eye 
patients, elevated levels of ROS in the tear fluid, increased expression and activity 
of ROS generating enzymes, and reduced levels of protective antioxidant enzymes 
on the ocular surface were observed.124–126 Such findings indicating the 
involvement of oxidative stress in dry eye have led to the consideration of 
employing components with antioxidant properties to target the oxidative 
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mechanisms on the ocular surface for the management and therapy of DED.127–129 
Vitamin A, vitamin C, and vitamin E are among the substances that possess 
antioxidant properties. Other components such as acetylcysteine, selenoprotein 
P, quercetin, gallic acid, epigallocatechin gallate, and n-propyl gallate are also 
being studied for their antioxidant properties and potential use in dry eye 
formulations.36,130  
Among the antioxidants that can be considered for topical ophthalmic dry eye 
formulations, vitamin A is of particular importance for the ocular surface. It can 
exist in several forms such as retinol, retinal, and retinoic acid, and is present in 
human tear fluid as retinol.131,132 On the ocular surface, vitamin A is involved in the 
correct differentiation of epithelial cells, re-epithelization of the cornea, and 
corneal wound healing.133 It plays an important role in reducing conjunctival 
keratinization, reversing squamous metaplasia, and increasing goblet cell 
number.133 Vitamin A containing ophthalmic formulations were evaluated in an 
experimental dry eye model134 as well as in DED patients, and were found to be 
effective in the treatment of the disease.135–137 Tseng et al.137 evaluated the clinical 
efficacy of 0.01% and 0.1% (weight/weight) topical all-trans retinoic acid ointment 
in treating DED and reported that all patients in the study showed improvements 
in symptoms, visual acuity, rose bengal staining, or Schirmer test after the use of 
the ointment. The authors stated that the topical vitamin A treatment resulted in 
the reversal of squamous metaplasia as evidenced by impression cytology. In 
another clinical study, treatment of DED patients with vitamin A eye drops (0.05% 
retinyl palmitate) resulted in a significant improvement in blurred vision, tear film 
break-up time, Schirmer scores, and findings of impression cytology.136 
1.4.3.3. Osmoprotectants 
Hyperosmotic stress is involved in inflammation and the pathogenesis of dry eye 
disease. The role of several substances such as levocarnitine (L-carnitine), betaine, 
and erythritol as osmoprotectants has been demonstrated in several in vitro 
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studies,138–140 as well as in an experimental dry eye.141 While the in vitro studies 
reported suppressive effects of the three osmoprotectants on the expression or 
activation of proinflammatory mediators, the experimental dry eye study 
demonstrated also that L-carnitine restored the loss of goblet cells caused by dry 
eye conditions. In a study published in 2011, Evangelista et al.142 compared three 
eye drops with different osmolarities (180 mOsm/L, 300 mOsm/L, 328 mOsm/L) 
and compositions, and found the low-osmolarity eye drop (180 mOsm/L) 
containing 1% L-carnitine to be the most effective in improving the quality and 
stability of the tear film in moderate dry eye patients.  
Another osmoprotectant substance is trehalose, a natural disaccharide that plays 
a key role in anhydrobiosis (capability of certain organisms of surviving complete 
dehydration).143 It has been demonstrated that trehalose is able to protect cells 
from desiccation and protect cell membranes and proteins from deactivation or 
denaturation.144,145 This unique characteristic of trehalose makes it attractive for 
DED treatment. In fact, a trehalose-based ophthalmic solution, when compared 
with six other commercially available eye drops indicated for DED, showed the 
highest efficiency in preventing cell death during desiccation in cultured human 
corneal epithelial cells, as well as in preserving cellular functionality.146 In an initial 
clinical study, Matsuo et al.147 found 100 and 200 mM trehalose eye drops to be 
safe and effective in the treatment of moderate-to-severe DED.  In another study, 
a 100 mM trehalose eye drop was compared with two commercially available eye 
drops, containing hyaluronan or cellulose, and was reported to be the most 
effective in the treatment of moderate to severe DED.148  
1.4.3.4. Novel components and technologies  
1.4.3.4.1. Liposomes 
A novel approach for formulating lipid-based ophthalmic preparations for DED 
treatment is the use of liposomes. Liposomes are spherical vesicles comprised of 
one or more lipid bilayers surrounding an aqueous core (Figure 1.11).149 They have 
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been widely investigated as a drug delivery system and employed for the delivery 
of various therapeutic agents.150–154 Lipophilic drugs are mostly entrapped in the 
lipid bilayer of the liposomes, whereas hydrophilic drugs are entrapped within the 
aqueous core. 
 
Figure 1.11. Liposome structure. 
 
Liposomes are usually composed of phospholipids and cholesterol (both 
components are present in the tear film). In the case of artificial tears, liposomes 
prepared with the last mentioned components may be beneficial in replenishing 
the tear film lipids and in restoring the tear film lipid layer. Indeed, 
phosphatidylcholine was shown to increase tear film stability in a model eye.155 
Another advantage of the use of liposomes in artificial tears is that they can carry 
lipophilic and hydrophilic substances that may be beneficial in the treatment of 
DED. Currently, a small number of liposomal formulations for DED treatment are 
available in the market in the form of sprays. These sprays are applied onto the 
closed eyelid and are thought to move across the eyelid margins and reach the 
tear film upon blinking. There is a limited number of published studies on the 
liposomal sprays for DED treatment (Table 1.4). 
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Authors Year Treatment groups 
Dieter et al.111 2006 - Liposomal spray Tears Again (Optrex ActiMist) 
- Triglyceride-containing gel Liposic 
Craig et al.112 2010 - Liposomal spray Tears Again (Optrex ActiMist) 
- Control: Saline spray 
Pult et al.113 2012 - Liposomal spray Optrex ActiMist 
- Liposomal spray DryEyesMist 
- Liposomal spray TearMist 
Table 1.4. Published studies on the liposomal sprays for DED treatment. 
 
The liposomal spray Tears Again (Optrex ActiMist) showed statistically significant 
clinical advantages over a triglyceride-containing gel (Liposic) in a randomized, 
controlled, cross-over study involving 74 patients suffering DED caused by a 
deficiency of the tear film lipid layer.111 The same liposomal spray was shown to 
significantly increase the thickness of the tear film lipid layer in normal eyes for up 
to 60 minutes after the application.112 More recently, Pult et al.113 compared this 
liposomal spray (Optrex ActiMist; Tears Again) with two other commercial 
liposomal sprays (Table 1.5) and found that only the previously mentioned spray 
(Optrex ActiMist), among the three, improved ocular comfort and the tear film 
stability significantly (10 minutes after the application).   
 
 Optrex ActiMist DryEyesMist TearMist 
Other brand 
names 
Tears Again, Liponit Hylite Eyerain 
Ingredients Soy lecithin, sodium 
chloride, ethanol, 
phenoxyethanol, vitamin 
A palmitate, vitamin E  
Liposomate 
isoflavonoids, sodium 
hyaluronate, camomile 
extract, N-
hydroxymethylglycinate, 
isotonic buffer solution 
Liposomate 
isoflavonoids, sodium 
hyaluronate, N-
hydroxymethylglycinate 
Table 1.5. Compared liposomal sprays for DED treatment. Adapted from Pult et al.113 
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1.4.3.4.2 In situ gelling systems 
In situ gelling systems are polymeric solutions that are able to form a gel when in 
contact with various body fluids. This phenomenon is known as sol-to-gel 
transition and occurs as a result of changes in parameters such as pH, 
temperature, and ions. In situ gelling systems can be used as drug delivery systems 
to extend the contact time of the formulation at the site of administration and 
provide a sustained release of the drug component. They have been employed in 
ocular, oral, rectal, and vaginal delivery, and as injectable systems to a specific site 
(e.g. tumor site).156 Among the investigated polymers as in situ gelling agents are 
chitosan, alginates, gellan gum, xyloglucans (e.g. tamarind seed polysaccharide; 
TSP), Carbopol, pluronics, and cellulose derivatives.157  
On the ocular surface, in situ gelling systems undergo gelation upon contact with 
the tear fluid and resist nasolacrimal drainage. Consequently, they extend the 
ocular residence time of topical ophthalmic formulations and increase 
bioavailability.158 Gellan gum, chitosan, alginate, TSP, and pluronics are among the 
polymers that have been investigated for use in topical ophthalmic formulations 
as in situ gelling agents. 
Gellan gum has been employed in a number of applications in the pharmaceutical 
industry.159,160 It has been incorporated into ophthalmic formulations to provide 
extended release and increased bioavailability of anti-glaucoma and anti-
inflammatory drugs.160 Gellan gum is a high molecular weight microbial 
polysaccharide. The polymer exists as a random coil in solution at high 
temperature and undergoes a conformational change to adopt a double helical 
structure with decreasing temperature. Subsequent aggregation of double helices 
leads to a three-dimensional network formation (Figure 1.12), producing a 
gel.161,162 The random coil-double helix transition temperatures of 1% high-acyl 
and 1% low-acyl gellan gum solutions were found to be 76°C and 25°C, 
respectively.162 Coil to double helix transition and the subsequent aggregation of 
the helices are influenced by the presence and type of cations, including the 
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cations of the tear film.163,164 The biocompatibility and unique gelling properties 
make gellan gum an interesting polymer for topical ophthalmic formulations, 
though it has not yet been employed in commercially available artificial tear 
formulations. 
 
 
Figure 1.12. Coil-helix and sol-gel transitions of gellan gum. Adapted from Miyoshi 
et al.164  
 
Polymers such as chitosan, alginate, TSP, and pluronics, have also been 
investigated for their gelling properties and for potential use as ocular in situ 
gelling systems. A number of studies showed that these polymers, used alone or 
in combination as in situ gelling systems in topical ophthalmic formulations, 
provided sustained release of the drug substances they were formulated with.165–
168 Table 1.6 summarizes some of these studies. Among these polymers, TSP, a 
natural polysaccharide obtained from the seeds of Tamarind (Tamarindus indica) 
tree, has been employed in an artificial tear formulation (HydraMed Lubricating 
Eye Drops) at a concentration of 0.2% in combination with sodium hyaluronate 
0.2%.  
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Gelling agent In situ sol-to-gel 
transition trigger 
Active ingredient Reference 
TSP (xyloglucan with a 
galactose removal of 44%) 
1.0%, 1.5%, and 2.0%  
• temperature: 
22–27°C 
Pilocarpine 
hydrochloride  
Miyazaki et 
al.165 (2001) 
Chitosan 0.25%  
Pluronic F-127 9%  
 
• pH: 6.9–7.0  
• temperature: 
35–37°C  
Timolol maleate  Gupta et al.166 
(2007) 
Chitosan 0.25%  
Gellan gum 0.5%  
• pH: 6.5-7.0  
• ion 
Timolol maleate  Gupta et al.167 
(2010) 
Sodium alginate 0.8%   
TSP 0.8% 
• ion Ketorolac 
tromethamine  
Gupta et al.168 
(2014) 
Table 1.6. In situ gelling systems used in topical ophthalmic formulations. TSP: tamarind 
seed polysaccharide. 
 
1.4.3.4.3. Cationorm: A novel cationic nanoemulsion 
Cationorm is an unpreserved cationic oil-in-water nanoemulsion (Figure 1.13) 
indicated for dry eye. It contains light and heavy mineral oil, cetalkonium chloride 
(cationic agent), tyloxapol and poloxamer 188 (non-ionic surfactants), glycerol 
(osmotic agent), tromethamine and tris hydrochloride (buffer), and purified 
water. The emulsion is obtained using the cationic nanoemulsion technology 
Novasorb developed by Novagali Pharma (Santen SAS).169  
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Figure 1.13. A lipid nanodroplet of the cationic oil-in-water emulsion. Adapted from 
Daull et al.170 
 
Electrostatic interaction between the positively charged nanodroplets of the 
emulsion and the negatively charged ocular surface leads to good spreading of the 
formulation over the ocular surface169 (Figure 1.14) and extends the ocular 
residence time of the formulation. The product is claimed to supplement all the 
layers of the tear film: the lipid content of the emulsion replenishes the lipid layer 
and reduces tear evaporation, whereas its osmotic agent is protective of the 
aqueous layer.  
 
 
Figure 1.14. Comparison of the dynamic contact angle and the base width of the 
cationic emulsion Cationorm with an anionic emulsion (Refresh Endura) instilled on 
rabbit eyes. Adapted from Lallemand et al.169  
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The interactions of Cationorm with human meibium and the tear film lipid layer 
were investigated in vitro and in vivo.171 In vitro studies were performed by 
forming pseudo-binary films of the nanoemulsion with the meibium collected 
from the lid margins of healthy volunteers, through Langmuir surface balance 
experiments, and showed that the nanoemulsion enhanced the thickness and 
elasticity of the meibium films. In vivo interactions of the formulation with the tear 
film lipid layer, observed by specular microscopy in a case study, resulted in 
increased thickness of the tear film lipid layer and supported the in vitro findings. 
Clinical studies demonstrated that the treatment with Cationorm resulted in the 
improvement of dry eye signs and symptoms, including  improved TBUT, lissamine 
green staining and corneal fluorescein staining results.172–174 The formulation 
showed good tolerability and safety in in vitro and clinical studies.173–175 Cationic 
nanoemulsions of cetalkonium chloride showed also anti-inflammatory properties 
in vitro in stimulated human cells and in a rat model of corneal scraping.176,177  
The Novasorb technology has also been used to develop cationic nanodroplets 
as a drug vehicle for both dry eye and non-dry eye ophthalmic formulations. A list 
of the products developed with the Novasorb technology169,178 can be seen in 
Table 1.7. 
 
Product Active ingredient Indication 
Cationorm – Dry eye 
Ikervis Cyclosporin A Severe dry eye 
Vekacia Cyclosporin A Vernal keratoconjunctivitis 
Catioprost Latanoprost  Glaucoma associated with 
ocular surface disease 
 Table 1.7. Products developed with the Novasorb technology. 
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1.4.3.4.4. PLL-g-PEG: A novel polymer system 
Poly(L-lysine)–graft–poly(ethylene glycol) (PLL-g-PEG) is a water-soluble, 
polycationic copolymer with a polypeptide backbone and PEG side chains. The 
copolymer has been shown to attach to negatively charged surfaces through 
electrostatic interaction due to the multiple positive charges on the PLL 
backbone.179,180 In vitro studies demonstrated that PLL-g-PEG reduces the 
frictional forces and enhance lubrication in aqueous environments.181,182 
This graft copolymer has been incorporated into an artificial tear formulation 
containing the demulcent glycerin (1%). A significant increase in tear film break-
up time in dry eye patients, compared with a commercially available propylene 
glycol and PEG containing artificial tear, was observed.183 The authors of the study 
attributed this effect to the interactions between the negatively charged epithelial 
cells and membrane-bound mucins of the ocular surface, the copolymer, and 
glycerin, resulting in extended ocular residence time and improved tear film 
stability. The formulation was evaluated as safe. 
1.4.3.4.5. Manuka honey 
Honey has been known to possess antimicrobial, anti-inflammatory and wound 
healing properties due to its acidic pH, low water content, high sugar content, and 
the glucose degradation product hydrogen peroxide.184–186 It has found medicinal 
applications, especially in wound healing. Manuka (Leptospermum species) 
honey, produced by the honey bees from the Manuka bush native to Australia and 
New Zealand, has recently gained interest for its stronger antimicrobial properties, 
attributed mainly to its high content of the antibacterial component 
methylglyoxal.187,188 Manuka honey has been investigated for ocular surface 
conditions such as blepharitis and post-operative corneal edema.76,189–191  
In a prospective pilot study, Albietz et al.192 investigated the ocular flora of DED 
patients and the effect of an antibacterial honey (MedihoneyTM Antibacterial 
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Honey; containing a mix of honeys including Manuka honey) on the flora. The 
authors found a significant difference in the count of bacterial colony forming 
units isolated from eyelid margins and conjunctiva of dry eye and non-dry eye 
groups. After a three times daily topical administration of the antimicrobial honey 
for a period of 3 months, a significant decrease in the bacterial count was observed 
in DED patients. The authors stated that the antibacterial properties of the honey 
could provide potential benefits in DED patients.  
There are currently two Manuka honey containing topical products with 
regulatory approval in Australia, New Zealand, and Europe, indicated for use in dry 
eye: an eye drop and a gel preparation. The eye drop preparation (Optimel 
Antibacterial Manuka+ Eye Drops) contains 16% Manuka honey in a saline solution 
with the preservative benzoic acid, whereas the gel preparation (Optimel 
Antibacterial Manuka+ Eye Gel) has a Manuka honey concentration of 98% and is 
unpreserved. The effects and safety of the 16% Manuka honey eye drop were 
evaluated in patients with contact lens (CL) related dry eye.193 A significant 
improvement in dry eye symptoms in patients with CL related dry eye was 
observed and the product was evaluated as safe in CL wearers. In another study, 
the efficacy of the Manuka honey containing eye drop and the gel preparation was 
assessed in patients with evaporative dry eye due to MGD, as an adjunctive 
therapy to conventional treatments (warm compresses, lid massage and 
preservative-free lubricant).194 Both the 16% Manuka honey eye drop and the 98% 
Manuka honey gel treatments resulted in a significant increase in meibum quality 
and gland expressibility, while significantly reducing lid margin isolated 
Staphylococcus spp. count and the need for the lubricant use in DED patients after 
an 8-week treatment, compared with the conventional therapy-only control 
group. The 16% drops also reduced the epithelial damage on the ocular surface. 
However, transient redness and stinging were reported as adverse effects in both 
studies.     
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1.5. Animal models of dry eye as a tool to assess 
the efficacy of artificial tears 
Animal models of dry eye are valuable tools for studying the pathophysiologic 
mechanisms of the disease and identifying disease biomarkers, as well as for the 
evaluation and comparison of the therapeutic efficacy of dry eye treatments. 
Though animal models do not always correlate well with the clinical setting, 
preclinical studies are an important step that may give insights regarding the 
safety and efficacy of therapeutic agents before clinical studies.  
Several aspects of the ocular surface and the tear film, such as ocular surface 
damage, tear production, tear osmolarity, and tear film stability, have been 
evaluated in animal models of dry eye.195 Examples of the tests that may be 
performed for such evaluations are listed in Table 1.8. Dogs, rabbits, mice, rats, 
pigs, and monkeys are among the animals that have been used in dry eye 
research.196–198 
 
Aspect to be evaluated Tests 
Ocular surface damage  o Ocular surface staining: 
- Fluorescein staining  
- Lissamine green staining 
- Rose bengal staining  
o Impression cytology 
Tear production o Schirmer test 
o Cotton thread test 
Tear osmolarity o Osmolarity measurement with an 
osmometer 
Tear film stability o Tear break-up time 
Table 1.8. Examples of the tests for the evaluation of the ocular surface and the tear film 
in animal models of dry eye. 
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Several in vivo models of dry eye have been developed, using different types of 
animals and approaches to induce the disease, depending on the focus of the 
investigation. In vivo models developed for studying the pathophysiologic 
mechanisms and causative factors of dry eye may employ genetic alterations of 
animals or other strategies such as closure of meibomian orifices by cauterization 
and surgical approaches (e.g. removal of lacrimal glands).199 Some of the most 
commonly employed methods to induce dry eye for efficacy assessment of DED 
treatments are administration of pharmaceutical agents, exposure to desiccating 
environmental stress, and mechanical approaches.  
Lacrimal gland injection of botulinum toxin B200 and topical ophthalmic 
administration of the antimuscarinic agent atropine201 have been employed to 
induce dry eye in animals. Another antimuscarinic agent scopolamine has been 
used in combination with desiccating environmental stress conditions to develop 
animal models of dry eye.202–206 Parameters such as humidity, air flow, and 
temperature  can be adjusted to achieve desiccating environmental stress in the 
room where animals are housed or in controlled environmental chambers.202–208 
Furthermore,  mechanical approaches such as holding the eye open with a 
speculum to prevent blinking have also been used to induce dry eye.209 Some of 
the dry eye treatments assessed using such dry eye models are listed in Table 1.9.  
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DED inducing conditions Model 
animal 
Evaluated dry eye treatments Reference 
Pharmaceutical agent administration 
Botulinum toxin B  
(injection to the lacrimal gland) 
 
Mouse  The topical steroid 
fluorometholone and the non-
steroidal anti-inflammatory drugs 
nepafenac and ketorolac 
Zhu et 
al.200 
(2012) 
Atropine sulfate 1% 
(topical ophthalmic 
administration)  
 
Rabbit Cyclosporine A-encapsulated 
liposomes vs. commercially 
available cyclosporine A emulsion 
(Restasis)  
Karn et 
al.201 
(2014) 
Desiccating environmental stress 
Dessicating environmental stress 
(RH: 25%2%, AF: 2-4 m/s, T: 
232°C)  
& placement of the animal on a 
jogging board (7.5 h/day) 
Rat D--hydroxybutyrate  
 
Nakamura 
et al.207 
(2005) 
Intelligently controlled 
environmental system  
(RH: 15.3% 3.0%, AF: 2.1 0.2 
m/s, T: 21°C–23°C)  
Mouse CMC+HA artificial tears (Optive 
Fusion) vs. CMC-only (Refresh 
Tears) vs.HA-only (Hycosan) 
artificial tears 
She et 
al.208 
(2015) 
Desiccating environmental stress + scopolamine administration 
Controlled environment chamber 
(RH: 30%, AF: 15 L/min, T: 21-
23°C)  
& SC scopolamine injection 
Mouse Topical omega-3 and omega-6 
fatty acids 
Rashid et 
al.202 
(2008) 
Controlled environment chamber 
(RH:20%, AF: 20 L/min,  
T:21–22°C) & scopolamine 
transdermal patch  
Mouse Oil-in-water emulsion containing 
natural triglycerides, a mixture of 
phospholipids, and glycerol 
(Emustil); alone or in combination 
with a commercially available SH 
0.2% formulation 
Scifo et 
al.203 
(2010) 
Exposure to an air draft and 30% 
ambient humidity 
& SC scopolamine hydrobromide 
injection 
Mouse Topical omega-3 fatty acids and 
hyaluronic acid mixtures  
Li et al.204 
(2014) 
Desiccating environmental stress 
(Placement of animals between 2 
fans for a continuous AF of 15 
L/min in a 25°C room with an 
ambient humidity of 30%) 
& SC scopolamine injection  
Mouse SH 0.18% artificial tears 
 
Oh et 
al.205 
(2014) 
Controlled environment chamber 
(RH: <25%, AF: 15 L/min, T: 20-
22C)  
& transdermal scopolamine patch  
Mouse Topical cationic emulsion of 
cyclosporine A (Ikervis) and its 
vehicle  
 
Daull et 
al.206 
(2016) 
Mechanical approaches for desiccation 
Holding the eye open with a 
speculum 
Rabbit Ocular lubricants containing SH, 
CMC, or HPMC  
Zheng et 
al.209 
(2014) 
Table 1.9. Examples of dry eye treatments evaluated in different animal models of dry 
eye.  RH: relative humidity, AF: airflow, CMC: carboxymethyl cellulose, HA: hyaluronic 
acid, SC: subcutaneous, SH: sodium hyaluronate, HPMC: hydroxypropyl methylcellulose. 
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BAK, a preservative widely used in ophthalmic formulations, has been shown to 
possess cytotoxic effects that may cause ocular surface damage and dry eye, as 
mentioned in Section 1.4.2.4. These effects of BAK have led to its exploration as a 
potential approach to induce dry eye in animal models. Topical administration of 
BAK has been employed to induce dry eye in mice and rabbits (Table 1.10).210–214 
As rabbit eyes are more similar to human eyes in terms of their size and have a 
larger exposed ocular surface that facilitates testing,199 rabbits may be preferable 
to mice.    
 
BAK treatment Main outcomes Model stability 
after the 
cessation of the 
BAK treatment 
Reference 
Mouse models 
0.2% twice daily; 
for 1 week 
↓ tear volume  
↓ tear break-up time 
↑ corneal fluorescein scores  
↑ rose bengal scores 
↑ inflammatory index 
Ultrastructural changes in the 
corneal epithelium 
Not observed Lin et al.210 
(2011) 
Rabbit models 
0.1% twice daily; 
for 2 weeks 
↓ tear secretion  
↑ fluorescein scores  
↑ rose bengal scores 
↓ goblet cell density 
↓ MUC5AC 
Histopathological and 
ultrastructural disorders of the 
cornea and the conjunctiva 
Not observed Xiong et 
al.211 
(2008) 
0.1% twice daily; 
for 2, 3, 4, or 5 weeks 
(groups 2W, 3W, 4W,  
and 5W, respectively) 
 
↓ tear secretion  
↑ fluorescein scores  
↓ goblet cell density 
↓ MUC5AC 
Histopathological and 
ultrastructural disorders of the 
cornea and the conjunctiva  
Group 5W the 
most stable;  
dry eye signs 
sustained for 2-3 
weeks 
Li et al.212 
(2012) 
Table 1.10. Animal models of dry eye developed with topical administration of BAK.   
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In vivo animal models have some disadvantages and limitations such as the 
feasibility and reproducibility issues and ethical considerations. In vitro and ex vivo 
animal models of dry eye are emerging as alternative tools to the in vivo models 
to investigate the mechanisms of dry eye and to evaluate the therapeutic efficacy 
of dry eye formulations. A number of two dimensional and three dimensional in 
vitro models using corneal or conjunctival cells have employed different methods 
to mimic dry eye conditions, including exposure to desiccating environmental 
conditions,215–217 osmotic stress,218 and inflammation-inducing agents.219 An 
interesting ex vivo dry eye model example is the porcine dry eye model developed 
by Choy et al.,220,221 using the whole porcine eyeball with conjunctiva tissue, 
lacrimal gland and the nictitating membrane in the system, and simulating dry eye 
by adjusting the lacrimation/blink interval in the model. Such models, once proven 
reliable and standardized, may be useful in dry eye research due to several 
potential advantages such as the opportunity of adjusting several parameters (e.g. 
blinking rate, temperature, humidity) as desired, increased practicality and 
reproducibility, and eliminating the use of laboratory animals along with the 
ethical considerations. 
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2. OBJECTIVES AND APPROACH 
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2.1. Main objective 
Dry eye disease (DED) is associated with impairments of the tear film and the 
ocular surface.2 Replenishing the tear film and restoring the ocular surface are 
crucial for the treatment of the disease. One of the most commonly employed 
therapeutic approaches in DED is the use of artificial tears. A large number of 
artificial tear formulations are commercially available. However, most of these 
formulations are water-based polymeric solutions, supplementing the aqueous 
phase of the tear film and providing only a temporary relief of the symptoms. 
Short ocular residence time, requiring frequent administration, is another 
drawback of many of these formulations.8 Current research in DED treatment falls 
short of addressing these issues.  
The main objective of this doctoral thesis was the design and development of 
novel artificial tear formulations for the treatment of dry eye disease. In order to 
accomplish this objective, specific objectives were set as indicated below.   
2.2. Specific objectives 
Objective 1: Development of artificial tear formulations containing novel 
components that replenish the tear film, with suitable physicochemical 
properties, optimum tolerance, and extended ocular residence time  
In order to achieve this objective, the following approach was taken: 
o Literature review on tear film to identify the key characteristics to mimic 
and the constituents that might achieve this, as well as on advances in DED 
treatments 
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o Design and preparation of five novel artificial tear formulations containing 
liposomes and/or bioadhesive polymers and/or in situ gelling polymers  
o Physicochemical characterization of the novel artificial tear formulations in 
terms of liposome size, pH, surface tension, viscosity, and osmolarity 
o Rheological evaluation of the artificial tears containing a gelling agent, 
upon simulating in situ gelling on the ocular surface  
o Assessment of the in vivo tolerance of the formulations in rabbits 
The results obtained are presented in Chapter 3 entitled “DEVELOPMENT AND 
CHARACTERIZATION OF NOVEL ARTIFICIAL TEAR FORMULATIONS”.   
Objective 2: Development of novel tools to evaluate the efficacy of the 
artificial tear formulations 
In order to achieve this objective, the following approach was taken: 
o Development of an in vivo dry eye model: Dry eye was induced in rabbits 
by twice a day topical ophthalmic administration of the preservative 
benzalkonium chloride (0.1%) for 15 days. The experimental dry eye model 
was characterized by assessing the ocular surface with corneal fluorescein 
staining and conjunctival impression cytology. 
The results obtained are presented in Chapter 3 entitled “DEVELOPMENT 
AND CHARACTERIZATION OF NOVEL ARTIFICIAL TEAR FORMULATIONS”.   
o Optimization of an ex vivo dry eye model: A porcine ex vivo anterior eye 
model developed at Aston University (UK) was optimized as a dry eye 
model, in collaboration with researchers from Aston University in the 
framework of the EDEN Project. 
 71 
The results obtained are presented in Chapter 4 entitled “PRELIMINARY EFFICACY 
STUDIES ON DRY EYE UTILIZING THE ASTON BIOLOGICAL ANTERIOR EYE MODEL”.   
Objective 3: Evaluation of the efficacy of the novel artificial tear 
formulations with preliminary studies 
In order to achieve this objective, preliminary efficacy studies were performed in 
the previously mentioned in vivo and ex vivo dry eye models: 
o Preliminary efficacy studies in the in vivo dry eye model over a 21-day 
treatment period 
The results obtained are presented in Chapter 3 entitled “DEVELOPMENT AND 
CHARACTERIZATION OF NOVEL ARTIFICIAL TEAR FORMULATIONS”.   
o Preliminary efficacy studies in the ex vivo dry eye model over an 18-hour 
treatment period 
The results obtained are presented in Chapter 4 entitled “PRELIMINARY EFFICACY 
STUDIES ON DRY EYE UTILIZING THE ASTON BIOLOGICAL ANTERIOR EYE MODEL”.   
Objective 4: Assessment of the effects of the novel artificial tear 
formulations on neutrophil extracellular trap (NET) formation as a proof 
of concept  
NETs are extracellular fibers of nuclear and granule components, produced by 
neutrophils through a process termed NETosis.222 Elevated levels of NETs on the 
ocular surface have been associated with DED pathogenesis.5,6  
In order to achieve this objective, the author collaborated with researchers from 
the University of Birmingham (UK) that work on NETosis. The following approach 
was taken: 
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o Isolation of neutrophils from the blood of a healthy donor 
o Incubation of the formulations with unstimulated and stimulated 
neutrophils and subsequent NET visualization  
The results obtained are presented in Chapter 5 entitled “NETOSIS STUDIES”. 
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3. DEVELOPMENT AND 
CHARACTERIZATION OF NOVEL 
ARTIFICIAL TEAR FORMULATIONS 
  
 74 
3.1. Introduction 
Artificial tears are considered the mainstay in the management of dry eye disease 
(DED).97  Numerous artificial tear formulations with a diverse range of components 
are currently available in the market. However, most of these formulations do not 
quite resemble natural tears in composition and do not aim to restore the tear 
film.29 Furthermore, they have a short ocular residence time and require repeated 
daily administration.8 
An ideal artificial tear formulation should contain both aqueous and lipid 
components to mimic natural tears, and have certain physicochemical properties 
such as neutral to slightly alkaline pH, suitable surface tension and viscosity.223 A 
surface tension near the physiological range of natural tears (that is reported to 
be 40–46 mN/m)86,87 provides a good spreading of the formulation over the ocular 
surface. For artificial tears that follow Newtonian behavior, the desirable viscosity 
would be in the physiological range of 1.0–8.3 mPa.s;17,93 whereas for those that 
follow non-Newtonian behavior, a dynamic viscosity in the same range would be 
suitable. Additionally, an ideal artificial tear formulation should be well tolerated 
on the ocular surface, provide extended ocular residence time, and be 
preservative-free. Artificial tears can be prepared isotonic or slightly hypotonic.  
This thesis aimed to develop novel artificial tear formulations that effectively 
replace and restore the altered, unstable tear film. With this purpose, the novel 
formulations incorporated both aqueous and lipid components and took into 
consideration parameters such as pH, surface tension, viscosity, and osmolarity. 
Five different artificial tear formulations were designed, developed, and 
characterized (Table 3.1).  
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Formulations 1 and 1a 
Liposomal formulations containing hydroxypropyl 
methylcellulose, levocarnitine, vitamin A, vitamin E, 
fructose, and borates   
Formulations 2 and 2a 
Liposomal formulations containing gellan gum, 
hydroxypropyl methylcellulose, levocarnitine, 
vitamin A, vitamin E, trehalose, electrolytes, and 
borates 
Formulation 3  
Formulation containing gellan gum, hydroxypropyl 
methylcellulose, levocarnitine, vitamin C, trehalose, 
electrolytes, and borates 
Table 3.1. The novel artificial tear formulations designed and developed in this thesis. 
 
Liposomes, which mimic the lipids of the tear film, were employed in the 
formulations to restore the lipid layer of the tear film. Bioadhesive polymers 
and/or in situ gelling polymers were used to provide bioadhesion and gelation on 
the ocular surface, respectively, in order to extend the ocular residence time of 
the formulations. Antioxidants, osmoprotectants, antidessicants, and components 
that protect the corneal epithelium were incorporated to obtain artificial tears 
that do not only provide a symptomatic relief of DED, but are also potentially 
effective in the treatment of the disease. The rationale for the use of each 
component is indicated in Table 3.2.  
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Component Rationale for use in the formulations 
Liposomes (made up of 
phosphatidylcholine and 
cholesterol)   
Resemble the lipids of the tear film, able to carry 
lipophilic and hydrophilic substances that may be 
beneficial in the treatment of DED 
Hydroxypropyl 
methylcellulose 
Bioadhesive polymer; interacts with the mucins 
of the tear film and extends the ocular residence 
time of the formulation 
Gellan gum In situ gelling polymer; undergoes sol-to-gel 
transition upon contact with the tear fluid  
Levocarnitine Osmoprotectant; potentially reduces 
hyperosmotic stress and the expression of 
proinflammatory cytokines 
Trehalose Osmoprotectant, antidessicant 
Vitamin A Antioxidant, protects corneal epithelial cells 
Vitamin C Antioxidant 
Vitamin E Antioxidant 
Fructose  Possesses high water retention properties 
Electrolytes  
(NaCl and KCl) 
Enhance the gelation of the formulations 
containing gellan gum upon contact with the 
tear fluid 
Borates Buffering agent 
Table 3.2. Formulation components and the rationale for their use. DED: dry eye disease. 
 
For the formulations incorporating the in situ gelling polymer gellan gum, the in 
situ gelling was mimicked and rheological evaluation was performed. 
Furthermore, in vivo tolerance of all of the artificial tears was assessed in rabbits. 
Another aim of the thesis was to develop a suitable in vivo platform for the efficacy 
studies of the artificial tears. With this purpose, an experimental model of dry eye 
was developed with topical ophthalmic administration of the preservative 
benzalkonium chloride in rabbits. Preliminary efficacy study of Formulation 3 was 
performed in the experimental dry eye model.  
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3.2. Materials and methods 
3.2.1. Materials 
Phosphatidylcholine obtained from soy lecithin (Phospholipon 90 G) was 
purchased from Lipoid GmbH (Ludwigshafen, Germany). Cholesterol, retinyl 
acetate (vitamin A), 2-phospho-L-ascorbic acid trisodium salt (vitamin C), DL-α-
tocopherol acetate (vitamin E), gellan gum (Gelzan™, Gelrite), boric acid, sodium 
tetraborate anhydrous, calcium chloride dihydrate, sodium bicarbonate, sodium 
hydroxide pellets, and benzalkonium chloride were supplied by Sigma-Aldrich Co. 
(St. Louis, MO, USA). Sodium chloride, potassium chloride, magnesium chloride 
hexahydrate, periodic acid (EMSURE), Schiff’s reagent, Papanicolaou’s solution 
1b Hematoxylin solution S, and the mounting medium Entellan new were 
purchased from Merck KGaA (Darmstadt, Germany). Chloroform (stabilized with 
ethanol), ethanol 70% v/v, ethanol 96% v/v, ethanol absolute, and xylene (mixture 
of isomers) were supplied by Panreac Química SLU (Barcelona, Spain). 
Hydroxypropyl methylcellulose was purchased from Abarán Materias Primas S.L. 
(Madrid, Spain), levocarnitine from Fagron Ibérica SAU (Barcelona, Spain), and 
sodium fluorescein (Colircusí Fluoresceína, 2%) from Alcon Cusí, S.A. (Barcelona, 
Spain). D-fructose and D-(+)-trehalose dihydrate were supplied by ThermoFisher 
(Kandel) GmbH (Karlsruhe, Germany), membrane disc filters (Supor 200) by Pall 
Corporation (Michigan, USA), and 24-well cell culture plates (Cellstar) by Greiner 
Bio-One (Kremsmünster, Austria). 
3.2.2. Animals 
A total of fourteen male New Zealand white rabbits (purchased from San Bernardo 
Farm, Navarra, Spain) were used: six rabbits (3.0–4.0 kg) for in vivo tolerance 
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studies and eight rabbits (1.5–2.2 kg) for the development of an animal model of 
dry eye. The animals were housed individually with free access to food and 
drinking water, in a room with an alternating 12-hour light/dark cycle. The room 
was maintained at 22°C with 50% relative humidity. Animal experiments were 
performed in accordance with the EU Directive 2010/63/EU for animal 
experiments, UK Animals (Scientific Procedures) Act 1986, and ARVO Statement 
for the Use of Animals in Ophthalmic and Visual Research. The study protocols 
were approved by the Complutense University of Madrid (Comité de 
Experimentación Animal & Comité de Ética de Experimentación Animal) and by 
Director General de Agricultura y Ganadería, Comunidad de Madrid (approval 
references: PROEX 011/16 and PROEX 316/16). 
3.2.3. Preparation of the artificial tear formulations 
3.2.3.1. Preparation of Formulations 1 and 1a   
Liposomes were prepared by the thin-film hydration method described by 
Bangham et al.224 and modified by Vicario-de-la-Torre et al.225 under aseptic 
conditions. The lipid phase of the liposomes consisted of phosphatidylcholine (PC), 
cholesterol (Chol), vitamin A (vit A), and vitamin E (vit E). Briefly, 400 mg of PC, 50 
mg of Chol, 4 mg of vit E, and 400 ng of vit A were dissolved in 25 mL of the organic 
solvent chloroform. The solvent was then evaporated using a rotary evaporator 
(Büchi Rotavapor R-205 coupled to B-490 Heating Bath, Vac V-500 Vacuum 
Pump, and V-800 Vacuum Controller, Massó Analítica S.A., Spain) under following 
conditions: 
i) at 33°C, 200 mbar, and 150 rpm; for 30 minutes  
ii) at 33°C, 100 mbar, and 150 rpm; for 30 minutes 
Compressed nitrogen (Alphagaz™, AL Air Liquide España S.A., Madrid, Spain) was 
applied for 5 minutes to remove any residual solvent. The resulting dry lipid film 
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was hydrated with 10 mL of an aqueous solution (1.8% fructose, 0.84% boric acid 
(H3BO3), and 0.08% sodium tetraborate anhydrous (Na2B4O7), with a pH of 7.0). 
For an optimal hydration of the lipid film upon the addition of the aqueous 
medium, the flask was first vigorously hand-shaken and subsequently placed on 
the rotary evaporator without vacuum (at 33°C and 200 rpm for 20 minutes). 
After hydration of the lipid film, the liposomal suspension was collected from the 
evaporating flask and maintained in the dark at room temperature (25°C) for 2 
hours to allow vesicle swelling. With the aim of obtaining a population of lipid 
vesicles that are homogenous in terms of size and structure, sonication and 
subsequent liposome extrusion were performed. Sonication was carried out in an 
ultrasonic bath (Ultrasons-H, J.P. Selecta S.A., Barcelona, Spain) at 5-10°C for 15 
minutes. Liposome extrusion was performed with an extruder (Lipex Extruder, 
Transferra Nanosciences Inc., Burnaby, BC, Canada), forcing the suspension 
through Nuclepore™ polycarbonate filters (Whatman International Ltd., Kent, UK) 
(pore size of 0.8 μm and 0.2 μm; 10 times each). After the extrusion process, the 
liposomal suspension was maintained at 2-8°C for 24 hours.   
The final formulations were obtained by diluting the liposomal suspension 1:2 with 
an aqueous solution containing 1% hydroxypropyl methylcellulose (HPMC), 0.2% 
or 0.8% levocarnitine (for Formulation 1 and Formulation 1a, respectively), 1.8% 
fructose, 0.84% H3BO3, and 0.08% Na2B4O7. Compositions of the formulations are 
indicated in Table 3.3. 
 
 
 
 
 
 80 
 FORMULATION 1 
Concentration (w:v) 
FORMULATION 1A 
Concentration (w:v) 
PC (liposomes) 2% 2% 
HPMC 0.5% 0.5% 
Levocarnitine 0.1% 0.4% 
Vitamin E 0.02% 0.02% 
Vitamin A 0.002% 0.002% 
Fructose 1.8% 1.8% 
H3BO3 0.84% 0.84% 
Na2B4O7 0.08% 0.08% 
Table 3.3. Compositions of Formulations 1 and 1a. Concentrations are expressed in 
percentage (weight/volume). PC: phosphatidylcholine, HPMC: hydroxypropyl 
methylcellulose, H3BO3: boric acid, Na2B4O7: sodium tetraborate anhydrous.  
 
3.2.3.2. Preparation of Formulations 2 and 2a 
Liposomes were prepared as described in Section 3.2.3.1, using an aqueous 
solution composed of 1.68% trehalose, 0.84% H3BO3, and 0.08% Na2B4O7. 
Formulations 2 and 2a (Table 3.4) were obtained by mixing the liposomal 
suspension with the following solutions that were prepared separately in the 
above-mentioned aqueous solution of trehalose and borates:   
o gellan gum 0.5% 
o HPMC 0.6% 
o levocarnitine 2% or 8% (for Formulation 2 and Formulation 2a, 
respectively) 
o NaCl 0.4% and KCl 0.4% 
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 FORMULATION 2 
Concentration (w:v) 
FORMULATION 2A 
Concentration (w:v) 
PC (liposomes) 0.5% 0.5% 
Gellan gum 0.25% 0.25% 
HPMC 0.12% 0.12% 
Levocarnitine 0.1% 0.4% 
Vitamin E 0.005% 0.005% 
Vitamin A 0.0005% 0.0005% 
NaCl 0.05% 0.05% 
KCl 0.05% 0.05% 
Trehalose 1.68% 1.68% 
H3BO3 0.84% 0.84% 
Na2B4O7 0.08% 0.08% 
Table 3.4. Compositions of Formulations 2 and 2a. Concentrations are expressed in 
percentage (weight/volume). PC: phosphatidylcholine, HPMC: hydroxypropyl 
methylcellulose, NaCl: sodium chloride, KCl: potassium chloride, H3BO3: boric acid, 
Na2B4O7: sodium tetraborate anhydrous.  
 
3.2.3.3. Preparation of Formulation 3 
The following solutions were prepared separately, in an aqueous solution of 1.68% 
trehalose, 0.84% H3BO3, and 0.08% Na2B4O7: 
o gellan gum 0.5% 
o HPMC 0.6% 
o levocarnitine 8%  
o Vitamin C 0.08% 
o NaCl 0.4% and KCl 0.4% 
These solutions were mixed to obtain Formulation 3 with the composition 
indicated in Table 3.5. 
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 FORMULATION 3 
Concentration (w:v) 
Gellan gum 0.25% 
HPMC 0.12% 
Levocarnitine 0.4% 
Vitamin C 0.01% 
NaCl 0.05% 
KCl 0.05% 
Trehalose 1.68% 
H3BO3 0.84% 
Na2B4O7 0.08% 
Table 3.5. Composition of Formulation 3. Concentrations are expressed in percentage 
(weight/volume). HPMC: hydroxypropyl methylcellulose, NaCl: sodium chloride, KCl: 
potassium chloride, H3BO3: boric acid, Na2B4O7: sodium tetraborate anhydrous. 
 
Compositions of the five artificial formulations developed in this thesis are 
indicated in Table 3.6. In all cases, solutions were sterilized either by steam 
sterilization (121°C, 20 minutes) or by filtration (pore size: 0.2 μm).  
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 Formulation 
1 
Formulation 
1a 
Formulation 
2 
Formulation 
2a 
Formulation 
3 
PC (liposomes) 2% 2% 0.5% 0.5% - 
Gellan gum - - 0.25% 0.25% 0.25% 
HPMC 0.5% 0.5% 0.12% 0.12% 0.12% 
Levocarnitine 0.1% 0.4% 0.1% 0.4% 0.4% 
Vitamin E 0.02% 0.02% 0.005% 0.005% - 
Vitamin A 0.002% 0.002% 0.0005% 0.0005% - 
Vitamin C - - - - 0.01% 
NaCl - - 0.05% 0.05% 0.05% 
KCl - - 0.05% 0.05% 0.05% 
Fructose 1.8% 1.8% - - - 
Trehalose - - 1.68% 1.68% 1.68% 
H3BO3 0.84% 0.84% 0.84% 0.84% 0.84% 
Na2B4O7 0.08% 0.08% 0.08% 0.08% 0.08% 
Table 3.6. Compositions of the five artificial tear formulations developed in this thesis. 
Concentrations are expressed in percentage (weight/volume). PC: phosphatidylcholine, 
HPMC: hydroxypropyl methylcellulose, NaCl: sodium chloride, KCl: potassium chloride, 
H3BO3: boric acid, Na2B4O7: sodium tetraborate anhydrous.  
 
3.2.4. Physicochemical characterization of the artificial tear 
formulations 
The artificial tear formulations were characterized in terms of liposome size, pH, 
surface tension, viscosity, and osmolarity.  
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3.2.4.1. Liposome size 
The particle size and the size distribution profile of liposomal vesicles were 
determined by dynamic light scattering (DLS, also referred to as photon 
correlation spectroscopy or quasi-elastic light scattering). In this technique, a 
monochromatic light beam, usually coming from a laser, is shot through the 
sample and the fluctuations of scattered light intensity are measured. 
Measurements were performed at room temperature and in triplicate, using the 
equipment Microtrac Zetatrac™ Particle Size & Zeta Potential Analyzer 
(Microtrac Europe GmbH, Meerbusch, Germany), operated through Microtrac 
FLEX software (Version 10.5.3). Results were expressed as mean ± standard 
deviation (SD) in nanometers (nm).   
3.2.4.2. pH 
The pH was determined at room temperature with a pH meter (GLP 22, Crison 
Instruments S.A., Barcelona, Spain). Measurements were performed in triplicate 
and results were expressed as mean ± SD. The pH meter was calibrated with 
standard buffer solutions of pH 4.0 and 7.0 before the measurements.  
3.2.4.3. Surface tension 
The surface tension of the formulations was determined with a tensiometer (Krüss 
K-11 Tensiometer, Krüss GmbH, Hamburg, Germany) employing the Wilhelmy 
plate method. In this method, the sample liquid is brought into contact with an 
optimally wettable plate that is suspended from a precision balance and 
perpendicularly oriented to the interface. The force exerted on the plate due to 
the wetting is measured and the surface tension is calculated by the equipment. 
The plate used in the analyses was made of platinum. Measurements were 
performed at 33°C (temperature of the ocular surface) and in triplicate. Results 
were expressed as mean ± SD in milliNewtons/meter (mN/m). 
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3.2.4.4. Viscosity 
The viscosity of the artificial tear formulations was determined with a rheometer 
(HAAKE RheoStress 1, ThermoFisher Scientific) using the parallel plate system 
(plate diameter=60 mm). For each formulation, the shear rate was increased 
stepwise in 20 steps from 0 to 1000 s-1 and each data point was measured at its 
equilibrium (steady state measurement). Measurements were performed at 33°C 
and in triplicate. The rheometer was operated through HAAKE RheoWin 
Measuring and Evaluation Software (Version: 4.30.0025). Results were expressed 
as mean ± SD in millipascal seconds (mPa.s). 
3.2.4.5. Osmolarity 
The osmolarity of the artificial tears was determined using a freezing-point 
osmometer (Gonotec Osmomat 3000). Measurements were performed in 
triplicate and results were expressed as mean ± SD in milliosmoles/liter (mOsm/L). 
3.2.5. Rheological studies 
To mimic the in situ gelling of the artificial tears on the ocular surface, the 
formulations were mixed with simulated tear fluid (STF)226 at a proportion of 25:7 
v/v (25 L of the formulation and 7 L of STF) and left for 150 seconds to allow gel 
formation. STF contained the electrolytes of tears that are involved in gel 
formation and consisted of 0.577% NaCl, 0.211% KCl, 0.013% CaCl2, 0.0076% 
MgCl2, and 0.218% NaHCO3. The rheological properties of the resultant gels were 
evaluated with a rheometer (HAAKE RheoStress 1, ThermoFisher Scientific; plate 
diameter=60 mm) at 33°C, employing rotational and oscillatory measurements.  
The flow curves were obtained both in the controlled rate (CR) and the controlled 
stress (CS) modes. In the CR mode, the shear rate was increased from 0-1000 s-1 in 
20 steps, and subsequently decreased from 1000-0 s-1 in 20 steps. In the CS mode, 
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the shear stress was set to increase in 20 steps from 0-5 Pa (Formulation 3) or 0-
5.1 Pa (Formulations 2 and 2a) and decrease to 0 Pa in 20 steps upon reaching the 
maximum set value. Ascending and descending flow curves were obtained by 
plotting shear stress versus shear rate in both the CR and the CS modes. The 
rheological behavior of the samples was observed and the dynamic viscosity at 
elevated shear rates was calculated in both the CR and the CS modes. The stress 
value at which the material yields and starts to flow, called the yield stress, was 
calculated in the CS mode. 
The linear viscoelastic region (LVR) of the samples, in which the material maintains 
its structure, was determined by an oscillatory stress sweep at the fixed frequency 
of 0.5 Hz. A stress value from within the LVR was chosen and used for a subsequent 
frequency sweep over the range of 0.1-100 Hz for further characterization of the 
samples. The elastic (storage) modulus G’ and the viscous (loss) modulus G” were 
evaluated. 
3.2.6. In vivo tolerance studies  
In vivo tolerance studies of the artificial tear formulations were performed in six 
male New Zealand white rabbits (each formulation was tested on a separate 
occasion). 30 μL of the artificial tear was administered in one eye of each animal 
every 30 min for 6 hours, whereas the contralateral eye received the same volume 
of non-preserved isotonic saline solution and served as control. Macroscopic 
evaluation of the ocular surface and the clinical signs was performed before the 
first instillation, and at 3, 6, and 24 hours after the first instillation, in compliance 
with the protocol previously described by Enríquez de Salamanca et al.227 Clinical 
signs (corneal opacity, conjunctival alterations, eyelid swelling, discharge, and 
indicators of animal discomfort) were assessed and graded from 0 to 2 according 
to the grading system used by the authors (Table 3.7).  
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      Grade 0     Grade 1         Grade 2 
Cornea No alterations Mild opacity Intense opacity 
Conjunctiva No alterations Mild hyperemia/ 
mild edema 
Intense 
hyperemia/ 
intense edema/ 
hemorrhage 
Eyelids No swelling Mild swelling Obvious swelling 
Discharge No discharge Mild discharge 
without  
moistened hair 
Intense discharge 
with moistened 
hair 
Discomfort No reaction Blinking Enhanced blinking/ 
intense tearing/ 
vocalizations 
Table 3.7. Grading system used in the in vivo tolerance studies. Adapted from Enríquez 
de Salamanca et al.227 
 
3.2.7. In vivo efficacy studies  
3.2.7.1. Development of an animal model of dry eye 
Study design 
Dry eye was induced in rabbits (n=8) by topical ophthalmic administration of the 
preservative benzalkonium chloride (BAK), following the protocols described by 
Xiong et al. and Li et al.211,212 To this, one eye of each animal was treated with 30 
μL of isotonic 0.1% BAK solution twice a day (8 A.M. and 7 P.M.) for 15 days. The 
contralateral eye received no treatment and served as a control. The ocular 
surface of the animals was evaluated prior to the BAK treatment (day 0), during 
the BAK treatment (day 7), and at the end of the BAK treatment (day 15) with two 
assays: corneal fluorescein staining and conjunctival impression cytology (CIC). 
Due to the irritated state of the animals and the slightly invasive nature of the 
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assay, in the control group on days 7 and 15, CIC samples were taken from four 
animals (n=4). 
i. Corneal fluorescein staining 
Corneal fluorescein staining has been used as an indicator of corneal damage. One 
drop of a 2% sodium fluorescein solution was instilled into the conjunctival sac. 
The cornea was evaluated after 2 minutes with a slit lamp (Kowa SL-15L, Kowa 
Company Ltd., Tokyo, Japan), using the cobalt blue filter. The cornea was divided 
into five zones (central, superior, inferior, nasal, and temporal; as in Figure 3.1) 
and each zone was assigned a grade from 0 to 4 according to the Efron Grading 
Scale.228 The grades of the five zones were summed up to obtain the total 
fluorescein score between 0–20.   
 
Figure 3.1. Corneal zones used in the grading of fluorescein staining. 
 
ii. Conjunctival impression cytology  
Samples of conjunctival cells were taken from the superior bulbar conjunctiva of 
the eyes by gently pressing a 5 mm x 5 mm membrane disc filter for 5 seconds 
with the help of a forceps. The samples with the cells obtained from the ocular 
surface were fixed in 96% ethanol for 30 minutes, stained with periodic acid-Schiff 
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(PAS) and hematoxylin, dehydrated and cleared.229 PAS staining was carried out in 
24-well culture plates with the following steps: 
o Distilled water: 10 minutes 
o Periodic acid (1%): 10 minutes 
o Distilled water: 3 minutes 
o Schiff’s reagent: 3 minutes 
o Distilled water: 5 minutes 
Hematoxylin staining and the subsequent dehydration and clearing of the samples 
(with increasing grades of ethanol and xylene, respectively) were carried out in 
staining dishes with the following steps: 
o Hematoxylin: 20 seconds 
o Distilled water: 5 minutes 
o Ethanol 70%: 2 minutes 
o Ethanol 96%: 2 times for 2 minutes 
o Ethanol 100%: 2 times for 2 minutes 
o Xylene: 9 minutes 
Samples were then mounted on a microscope slide with the mounting medium 
Entellan and examined under microscope (Nikon Eclipse Ci, Nikon Corporation, 
Tokyo, Japan) after a 24-hour waiting period. Microscopic evaluation was 
performed at 400X magnification following the protocol described by Zuazo et 
al.,230 which uses a semi-quantitative estimation of five cytological criteria chosen 
according to the grading system described by Nelson et al.231 Each cytological 
criterion was assigned a score according to Table 3.8 and the scores of the five 
criteria were summed up to obtain the total cytological score. Images were 
captured using Nikon NIS-Elements Imaging Software (Version 4.0). 
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Cytological criteria Reference range 
Cellularity 0: abundant 
1: moderate 
2: scarce 
Cell-cell contact 0: associated cells 
1: associated cells and isolated cells 
2: isolated cells only 
Nucleus/cytoplasm ratio 0: 1/2 
1: 1/3 – 1/4 
2: >1/5 
Goblet cells 0: abundant (≥30) 
1: moderate (<30) 
2: scarce (<10) 
3: absent (<3) 
Metaplasia 0: absent 
1: incipient 
2: moderate 
3: advanced 
Table 3.8. Cytological criteria and the relative reference ranges used in the evaluation of 
the epithelial and the goblet cells. Adapted from Zuazo et al.230 Goblet cell count was 
presented as cells/image field of view at 400X magnification. 
 
The total cytological score of the five criteria was also expressed according to 
Nelson grading (Table 3.9). 
Nelson grade Cytological score 
0 0–3 
1 4–5 
2 6–9 
3 ≥10 
Table 3.9. Nelson grading in relation to the cytological score. Adapted from Zuazo et 
al.230 
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3.2.7.2. Preliminary efficacy study 
Preliminary efficacy study of Formulation 3 was performed in the experimental 
dry eye model described in Section 3.2.7.1, immediately after inducing dry eye in 
rabbits with a 15-day BAK treatment. The dry eye models (n=8) were divided into 
two groups: the treatment group (n=6) and the control group (n=2). The treatment 
group was treated with 30 μL of the test formulation three times a day (8 A.M., 
1.30 P.M., and 7 P.M.) for a period of 21 days. The control group received the same 
volume of a non-preserved isotonic saline solution with the same frequency for 21 
days. The contralateral eye of each animal, not treated with BAK in the previous 
study (non-dry eye; “healthy” eyes), received a non-preserved isotonic saline 
solution during this study and they were used as a reference to normal conditions 
(reference group; n=8).  Efficacy of the formulation was evaluated with corneal 
fluorescein staining and CIC, as described in Section 3.2.7.1, on days 7, 14, and 21 
of the treatment. Fluorescein scores and cytological scores obtained at the end 
(on day 15) of the previous experimental dry eye study were accepted as baseline 
scores for this study. In the reference group, on days 7, 14 and 21, CIC samples 
were taken from four animals (n=4). 
3.2.7.3. Statistical analysis 
Statistical analyses of fluorescein and cytological scores were performed with 
Mann-Whitney test, using the GraphPad Prism software (Version 7.0a), as the 
scores were assigned based on distinct grading scales. P-values were two-tailed 
and P<0.05 was considered to be statistically significant. 
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3.3. Results  
3.3.1. Physicochemical characterization of the artificial tear 
formulations 
The results obtained in the characterization of the physicochemical properties of 
the five artificial tear formulations are reported in Table 3.10. Data are expressed 
as mean ± SD.  
 
 Formulation 
1 
Formulation 
1a 
Formulation 
2 
Formulation 
2a 
Formulation 
3 
Liposome size 
(nm) 
194.40 ± 1.80 191.03 ± 9.72 200.07 ± 4.37 194.53 ± 0.55 – 
pH 6.96 ± 0.03 6.99 ± 0.03 7.58 ± 0.03 7.41 ± 0.05 7.06 ± 0.01 
Surface tension 
(mN/m) 
48.73 ± 0.15 46.37 ± 2.75 45.57 ± 1.55 44.60 ± 0.26 46.97 ± 0.50 
Viscosity* 
(mPa.s) 
10.25 ± 0.52 12.08 ± 0.19 4.01 ± 0.06 4.64 ± 0.12 3.64 ± 0.02 
Osmolarity 
(mOsm/L) 
222.67 ± 2.08 241.33 ± 0.58 250.33 ± 0.58 265.67 ± 1.15 272.67 ± 3.06 
Table 3.10. Results obtained in the physicochemical characterization of the five artificial 
tear formulations. Formulation 3 did not contain liposomes. Data are expressed as mean 
± SD. *Mean value (± SD) within the shear rate interval of 200-1000 s-1.     
 
The liposomal vesicles of the liposome-containing formulations (Formulations 1, 
1a, 2, and 2a) showed a unimodal size distribution (Figures 3.2 and 3.3). 
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Figure 3.2. Size distribution of the liposomal vesicles of Formulations 1 and 1a. 
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Figure 3.3. Size distribution of the liposomal vesicles of Formulations 2 and 2a. 
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The artificial tears followed Newtonian behavior as can be seen in rheograms 
illustrated in Figure 3.4. Formulations 1 and 1a had higher viscosities than the 
other formulations (within the shear rate interval of 200-1000 s-1). 
 
 
Figure 3.4. Rheograms of the artificial tear formulations. 
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The physicochemical properties of the liposome-containing artificial tear 
formulations were compared with their corresponding initial liposomal 
suspensions (Tables 3.11 and 3.12). The comparisons revealed that the liposome 
size, surface tension, and viscosity increased upon dilution of the liposomal 
suspensions with their corresponding polymeric solutions, whereas the pH 
remained similar.  
 
 Liposomal 
suspension 1 
Formulation 1 Formulation 1a 
Liposome size (nm) 172.57 ± 0.47 194.40 ± 1.80 191.03 ± 9.72 
pH 6.96 ± 0.02 6.96 ± 0.03 6.99 ± 0.03 
Surface tension (mN/m) 25.70 ± 0.66 48.73 ± 0.15 46.37 ± 2.75 
Viscosity* (mPa.s) 1.12 ± 0.04 10.25 ± 0.52 12.08 ± 0.19 
Table 3.11. Comparison of the physicochemical properties of Liposomal suspension 1, 
Formulation 1, and Formulation 1a. Data are expressed as mean ± SD. *Mean value (± 
SD) within the shear rate interval of 200-1000 s-1.     
 
 
 Liposomal 
suspension 2 
Formulation 2 Formulation 2a 
Liposome size (nm) 164.40 ± 1.91 200.07 ± 4.37 194.53 ± 0.55 
pH 7.45 ± 0.01 7.58 ± 0.03 7.41 ± 0.05 
Surface tension (mN/m) 26.93 ± 0.42 45.57 ± 1.55 44.60 ± 0.26 
Viscosity* (mPa.s) 1.12 ± 0.03 4.01 ± 0.06 4.64 ± 0.12 
Table 3.12. Comparison of the physicochemical properties of Liposomal suspension 2, 
Formulation 2, and Formulation 2a. Data are expressed as mean ± SD. * Mean value (± 
SD) within the shear rate interval of 200-1000 s-1.     
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3.3.2. Rheological studies 
The flow curves of the gels obtained in the controlled rate (CR) mode are 
illustrated in Figure 3.5. Pseudoplastic behavior and a hysteresis area between the 
ascending and the descending flow curves are observed. Gels seem to show 
thixotropic behavior (the viscosity values obtained during the stepwise increase of 
the shear rate are greater than the ones obtained during the stepwise decrease). 
 
 
Figure 3.5. Flow curves of the gels in the CR mode.  
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The dynamic viscosity values of the gels at elevated shear rates (800-1000 s-1) in 
the CR mode are repoted in Table 3.13. 
 
Analyzed sample Dynamic viscosity (mPa.s) 
Formulation 2 – STF 2.77±0.15 
Formulation 2a – STF 2.83±0.06 
Formulation 3 – STF 2.97±0.25 
Table 3.13. Dynamic viscosities of the gels at elevated shear rates (800-1000 s-1) in the 
CR mode. 
 
When the flow curves are obtained in the controlled stress (CS) mode (Figure 3.6), 
a yield stress can be observed in addition to the pseudoplastic behavior, reflecting 
a Herschel-Bulkley fluid model. The materials exhibit elastic behavior below the 
yield stress; whereas above the yield stress they exhibit viscous behavior and flow. 
The yield stress and the dynamic viscosity values (at elevated shear rates; 800-
1100 s-1) of the gels are repoted in Table 3.14.  
 
Analyzed sample Yield stress (Pa) Dynamic viscosity (mPa.s) 
Formulation 2 – STF 1.96±0.29 2.95±0.21 
Formulation 2a – STF 1.98±0.04 3.00±1.17 
Formulation 3 – STF 1.64±0.01 2.85±0.35 
Table 3.14. Yield stress and dynamic viscosity values of the gels (at elevated shear rates; 
800-1100 s-1) in the CS mode. 
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Figure 3.6. Flow curves of the gels in the CS mode.  
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The linear viscoelastic region of each gel was determined with an oscillatory stress 
sweep (Figure 3.7). The stress values chosen from the LVR for the subsequent 
frequency sweep measurements were as follows: 0.4 Pa for Formulations 2 and 
2a, and 0.1 Pa for Formulation 3. 
 
 
Figure 3.7. Oscillatory stress sweep measurements of the gels showing the linear 
viscoelastic regions. 
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The results obtained with the frequency sweep (Figure 3.8) showed that the elastic 
modulus G’ is greater than the viscous modulus G’’, indicating that the gels exhibit 
viscoelastic properties with elastic behavior. At intermediate oscillation 
frequencies (1-10 Hz), the dynamic moduli G’ and G’’ demonstrate low 
dependency on the frequency. At higher oscillation frequencies (i.e. greater than 
20 Hz), the viscous modulus G’’ increases more rapidly than the elastic modulus 
G’, indicative of a strong loss in elastic response.  
 
 
Figure 3.8. Frequency sweep measurements of the gels.  
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3.3.3. In vivo tolerance studies  
Prior to the experiments, all of the animals had a normal ocular surface and 
showed no clinical signs or indicators of discomfort (grade 0). During the 
experiments, the animals showed neither indicators of discomfort nor clinical 
signs (grade 0) generated by any of the artificial tear formulations within 24 hours 
after the first instillation (Table 3.15). 
Cornea No alterations (grade 0) 
Conjunctiva No alterations (grade 0) 
Eyelids No swelling (grade 0)  
Discharge No discharge (grade 0) 
Discomfort No reaction (grade 0) 
Table 3.15. Results of the in vivo tolerance studies. 
 
3.3.4. In vivo efficacy studies  
3.3.4.1. Development of an animal model of dry eye 
Corneal fluorescein staining 
Fluorescein scores of the untreated control group and the BAK group on days 0, 7, 
and 15 of the BAK treatment are reported in Table 3.16. 
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Day Control group BAK group 
0 2.13 ± 1.73 1.75 ± 1.91 
7 2.14 ± 2.41 6.86 ± 3.39 
15 0.88 ± 1.73 13.75 ± 5.18 
Table 3.16. Fluorescein scores on days 0, 7, and 15 of the BAK treatment. 
 
No significant differences were found in fluorescein scores between the BAK group 
and the control group at baseline (day 0). Nevertheless, fluorescein scores 
increased significantly in the BAK group on day 7 (P<0.05) and day 15 (P<0.001) 
compared with baseline and the control group. In the control group, no significant 
differences from baseline were observed on days 7 and 15 (Figure 3.9). 
 
 
Figure 3.9. Fluorescein scores on days 0, 7, and 15 of the BAK treatment. Sum of 0-
4 scale grading for 5 corneal zones. *P<0.05, **P<0.01, ***P<0.001. 
 
 104 
Representative images of corneal fluorescein staining in BAK-treated eyes prior to 
the BAK treatment (day 0), during the BAK treatment (day 7), and at the end of 
the BAK treatment (day 15) are illustrated in Figure 3.10. 
 
 
Figure 3.10. Representative images of corneal fluorescein staining in BAK -treated 
eyes. Day 0: No obvious staining was observed prior to the BAK treatment. Day 7: 
Staining was observed. Day 15: Diffuse and heavier staining was observed in all 
five corneal zones. 
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Conjunctival impression cytology  
Cytological scores and corresponding Nelson grades of the untreated control 
group and the BAK group on days 0, 7, and 15 of the BAK treatment are reported 
in Table 3.17.  
 
Day 
Control group BAK group 
Cytological score 
Nelson 
grade 
Cytological score 
Nelson 
grade 
0 0.75 ± 0.46 0 0.63 ± 0.52 0 
7 1.75 ± 1.26 0 6.71 ± 0.95 2 
15 1.75 ± 1.26 0 8.25 ± 1.58 2 
Table 3.17. Cytological scores and corresponding Nelson grades on days 0, 7, and 15 of 
the BAK treatment. 
 
No significant differences were found in cytological scores between the BAK group 
and the control group at baseline (day 0). Cytological scores increased significantly 
in the BAK group on days 7 and 15 compared with baseline (P<0.001) and the 
control group (P<0.01). In the control group, no significant differences from 
baseline were observed on days 7 and 15 (Figure 3.11). 
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Figure 3.11. Cytological scores on days 0, 7, and 15 of the BAK treatment. *P<0.05, 
**P<0.01, ***P<0.001. 
 
Representative images of conjunctival impression cytology in BAK-treated eyes 
prior to the BAK treatment (day 0), during the BAK treatment (day 7), and at the 
end of the BAK treatment (day 15) are illustrated in Figure 3.12. 
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Figure 3.12. Representative images of conjunctival impression cytology in BAK-
treated eyes. Day 0: Baseline, prior to the BAK treatment, Nelson grade 0. 
Epithelial cells (violet): small and abundant. Cell-cell contact: very high, all cells are 
associated. Nucleus/cytoplasm ratio: 1/2. Goblet cells (purple): plump, well-
defined, and abundant. Day 7: Nelson grade 2. Epithelial cells: larger and scarce. 
Cell-cell contact: diminished, cells are mostly isolated. Nucleus/cytoplasm ratio: 
1/3–1/4. Goblet cells: smaller, poorly defined, and moderate in number. Day 15: 
Nelson grade 2. Epithelial cells: larger, abnormally shaped, and scarce. Cell-cell 
contact: low. Nucleus/cytoplasm ratio: >1/5. Goblet cells: absent. Scale bars: 25 
m. 
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3.3.4.2. Preliminary efficacy study  
Corneal fluorescein staining 
The fluorescein score of the dry eye models obtained at the end of the previous 
experimental dry eye study (13.75 ± 5.18; n=8) was accepted as the baseline score 
(day 0) for the control and the treatment groups of this study, whereas the score 
of the untreated eyes from the previous study (0.88 ± 1.73; n=8) was accepted as 
the baseline score for the reference group. Fluorescein scores of the control group 
(dry eye models treated with isotonic saline solution; n=2 after baseline), the 
treatment group (dry eye models treated with Formulation 3; n=6 after baseline), 
and the reference group (“healthy” eyes treated with isotonic saline solution; n=8 
after baseline) during the efficacy study are reported in Table 3.18.  
 
 
 
 
Table 3.18. Fluorescein scores during the preliminary efficacy study. 
 
In the treatment group, fluorescein scores decreased significantly (P<0.01 
compared with baseline) and appeared to return to the normal values (P>0.05 
compared with the reference group) already on day 7 (Figure 3.13). In the control 
group, the first statistically significant decrease from baseline was observed on 
day 14 (P<0.05), with the values returning to normal levels on day 21 (P>0.05 
compared with the reference group). Compared with the control group, 
significantly lower fluorescein scores were observed in the treatment group on 
days 14 and 21 (P<0.05). 
Day Control group Treatment group Reference group 
0 13.75 ± 5.18 13.75 ± 5.18 0.88 ± 1.73 
7 6.00 ± 2.83 1.50 ± 1.52 0.38 ± 0.74 
14 2.50 ± 0.71 0.33 ± 0.52 0.50 ± 0.76 
21 1.00 ± 0.00 0.00 ± 0.00 0.25 ± 0.46 
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Figure 3.13. Fluorescein scores and the statistical significance during the 
preliminary efficacy study A) between groups on each test day, B) between each 
test day inside the control group, C) between each test day inside the treatment 
group. The fluorescein score of the treatment group on day 21 was 0.00 ± 0.00; it is 
represented with a closed circle in the bar charts (A and C). The reference group 
had no statistically significant difference between any test day throughout the 
study and was not illustrated with a separate bar chart. *P<0.05, **P<0.01, 
***P<0.001. 
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Representative images of corneal fluorescein staining in the experimental model 
of dry eye prior to the treatment with the test formulation (day 0) and at days 7, 
14, and 21 of the treatment are illustrated in Figure 3.14. 
 
Figure 3.14. Representative images of corneal fluorescein staining in the 
experimental model of dry eye treated with the test formulation.  Day 0: 
Experimental dry eye, prior to the treatment with the test formulation. Diffuse and 
heavy staining was observed in all five corneal zones. Day 7: Staining was 
remarkably diminished; with a few light patches observed in the central corneal 
zone. Days 14 and 21: No obvious staining was observed. 
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Conjunctival impression cytology  
The cytological score of the dry eye models obtained at the end of the previous 
experimental dry eye study (8.25 ± 1.58; n=8) was accepted as the baseline score 
(day 0) for the control and the treatment groups of this study, whereas the score 
of the untreated eyes from the previous study (1.75 ± 1.26; n=4) was accepted as 
the baseline score for the reference group. Cytological scores and the 
corresponding Nelson grades obtained during the preliminary efficacy study are 
reported in Table 3.19 (n=2 for the control group, n=6 for the treatment group, 
and n=4 for the reference group after baseline).   
Day 
Control group Treatment group Reference group 
Cytological 
score 
Nelson 
grade 
Cytological 
score 
Nelson 
grade 
Cytological 
score 
Nelson 
grade 
0 8.25 ± 1.58 2 8.25 ± 1.58 2 1.75 ± 1.26 0 
7 7.50 ± 2.12 2 4.50 ± 0.84 1 1.00 ± 0.82 0 
14 7.50 ± 0.71 2 3.17 ± 1.47 0 1.50 ± 1.29 0 
21 6.50 ± 0.71 2 0.33 ± 0.52 0 1.00 ± 1.41 0 
Table 3.19. Cytological scores and the corresponding Nelson grades during the 
preliminary efficacy study. 
 
Compared with baseline, cytological scores decreased significantly in the 
treatment group at day 7 (P<0.001) and continued to decrease on the next test 
days, whereas no statistically significant difference from baseline was observed in 
the control group on any test day (Figure 3.15). Compared with the control group, 
significantly lower cytological scores were observed in the treatment group at day 
21 (P<0.05). In the treatment group, no more significant differences were found 
on day 14 compared with the reference group. Cytological scores of the control 
group were higher than the reference group throughout the study (days 7, 14, and 
21); however, statistically significant results were not obtained, probably due to 
the small total sample size in these particular comparisons: n=2 for the control 
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group and n=4 for the reference group (the guide of the statistics software used 
in the analyses indicates that the Mann-Whitney test always gives a P-value 
greater than 0.05 when the total sample size is seven or less, no matter how much 
the groups differ232).  
 
Figure 3.15. Cytological scores and the statistical significance during the 
preliminary efficacy study A) between groups on each test day, B) between each 
test day inside the control group (no significant difference was observed between 
any test day), C) between each test day inside the treatment group. The reference 
group had no statistically significant difference between any test day throughout 
the study and was not illustrated with a separate bar chart. *P<0.05, **P<0.01, 
***P<0.001. 
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Representative images of conjunctival impression cytology in the experimental 
model of dry eye prior to the treatment with the test formulation (day 0) and at 
days 7, 14, and 21 of the treatment are illustrated in Figure 3.16. 
 
 
Figure 3.16. Representative images of conjunctival impression cytology in the 
experimental model of dry eye treated with the test formulation. Day 0: 
Experimental dry eye, prior to the treatment with the test formulation, Nelson 
grade 2. Epithelial cells (violet): large, abnormally shaped, and scarce . Cell-cell 
contact: low. Nucleus/cytoplasm ratio: >1/5. Goblet cells (purple): absent. Day 7: 
Nelson grade 1. Epithelial cells: smaller but mostly polygonal, and moderate in 
number. Cell-cell contact: moderate. Nucleus/cytoplasm ratio: 1/3–1/4. Goblet 
cells: smaller than normal, poorly defined, and moderate in number. Day 14: 
Nelson grade 0. Epithelial cells: small and abundant. Cell-cell contact: high. 
Nucleus/cytoplasm ratio: 1/2. Goblet cells: plump, mostly well-defined, and 
moderate in number. Day 21: Nelson grade 0. Epithelial cells: small and abundant. 
Cell-cell contact: very high, all cells are associated. Nucleus/cytoplasm ratio: 1/2. 
Goblet cells: plump, well-defined, and abundant. The state and the number of the 
epithelial and the goblet cells have returned to normal. Scale bars: 25 m. 
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3.4. Discussion  
Dry eye disease is associated with alterations and instability of the tear film; 
therefore, restoring the tear film is fundamental in its management. This study 
aimed at developing novel artificial tear formulations that resemble natural tears 
and restore the impaired tear film and the ocular surface in DED. Liposomes, 
consisting of phosphatidylcholine and cholesterol, were employed to replenish 
the lipids of the tear film. The in situ gelling polymer gellan gum was incorporated 
because of its unique gel-forming property when in contact with certain ions 
present in tears,161–164 with the aim of resisting the lacrimal drainage and 
extending the ocular residence time of the formulation. HPMC was used to 
provide bioadhesion102 and increase the ocular residence time. Antioxidants 
vitamin A, vitamin C, vitamin E, and osmoprotectants levocarnitine and trehalose 
were incorporated to enhance the potential efficacy of the artificial tears in the 
treatment of DED.   
When formulating an artificial tear, the key physicochemical parameters such as 
pH, surface tension, viscosity, and osmolarity should be taken into consideration. 
Human tears have a pH of 7.0–7.5,79,80 and a buffering capacity that prevents the 
ophthalmic formulations within the pH range of 6.6–9.0 from causing 
discomfort.82–84 The formulations developed in this thesis had neutral to slightly 
alkaline pH (7.0–7.6), very similar to the pH of human tears, suggesting optimum 
tolerance of the formulations on the ocular surface in terms of their pH.  
The surface tension of natural tears is reported to be 40–46 mN/m,86,87 and the 
viscosity 1.0–8.3 mPa.s.17,93 The surface tension of an ophthalmic formulation 
affects its interaction with the tear film and spreading ability over the ocular 
surface.89 The viscosity, if excessively high, can cause non-uniform mixing of the 
formulation with natural tears, blurred vision, and discomfort. The surface tension 
of the formulations developed in this thesis ranged from 44.6 to 48.7 mN/m, and 
the viscosity from 3.6 to 12.1 mPa.s, suggesting good spreading of the 
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formulations over the ocular surface without causing tear film instability, blurred 
vision, or discomfort. Furthermore, the liposomal vesicles of the liposome-
containing artificial tears had a suitable size for a topical ophthalmic formulation.  
Tear hyperosmolarity is one of the main mechanisms in DED pathogenesis; it may 
lead to inflammation and tear film instability.4 Therefore, restoring the 
physiological tear osmolarity and protecting the ocular surface from hyperosmotic 
stress is important in DED management. With this purpose, the formulations 
developed in this thesis incorporated levocarnitine for its osmoprotectant 
properties,138–141 and trehalose for both osmoprotectant and antidessicant 
properties.144–146 In fact, trehalose eye drops (100 mM and 200 mM) were 
previously found effective in the treatment of moderate to severe DED in an initial 
4-week clinical study.147 Furthermore, in a 4 week cross-over clinical study, 100 
mM trehalose eye drops were found to be more effective in improving dry eye 
signs in moderate to severe DED patients compared with two commercially 
available eye drops containing either hyaluronan or hydroxyethylcellulose.148 
Considering these findings and the increased tear osmolarity in dry eye, it can be 
postulated that the artificial tears developed in this thesis, which are slightly 
hypotonic (with osmolarity values ranging from 222.7 to 272.7 mOsm/L) and 
incorporate components with osmoprotectant and antidessicant properties, 
would be suitable for DED patients with potential beneficial effects.233,234  
Gellan gum has been employed in ophthalmic preparations as an in situ gelling 
agent in order to provide sustained release and improve bioavailability of anti-
inflammatory and and anti-glaucoma agents;159,160 however, it has not yet been 
utilized in commercially available artificial tears. The rheological data obtained in 
this study showed that the gellan gum containing formulations (Formulations 2, 
2a, and 3) behaved as in situ gelling systems, which may be attributed to the ability 
of three-dimensional network formation of the gelling polymer in presence of 
certain ions in tears. The gelling formulations exhibited viscoelastic properties 
with elastic gel behavior (storage modulus>loss modulus) when mixed with STF. 
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The dynamic viscosities of the simulated in situ gels at elevated shear rates (800–
1100 s-1) ranged from 2.8–3.0 mPa.s. Such dynamic viscosities in the physiological 
range of natural tears and the pseudoplastic or “shear-thinning” properties 
exhibited by the tested gels could prevent discomfort after administration and 
avoid damage to the ocular surface during blinking where high shear rates are 
present (estimated to be between 4250–28500 s-1).17,235 Additionally, the in situ 
gel forming artificial tears may provide extended ocular residence time after 
topical ophthalmic administration in DED treatment. 
As shown in the results of this work, the in vivo tolerance studies indicated that 
the formulations resulted well-tolerated in rabbit eyes. In fact, they do not 
generate any indicators of discomfort or undesirable alterations on the ocular 
surface of rabbits. 
One of the aims of this thesis was to develop an in vivo dry eye model in rabbits as 
a tool to evaluate the efficacy of artificial tears. The preservative BAK has shown 
to be cytotoxic for corneal and conjunctival epithelial cells. BAK has been 
previously utilized to successfully induce dry eye in rabbits.211,212 In these previous 
studies, a 2-week treatment with BAK resulted in dry eye signs including decreased 
tear secretion, increased fluorescein and rose bengal scores, and decreased goblet 
cell density. Li et al.212 investigated the stability of the rabbit dry eye models 
induced with 0.1% BAK treatment for different durations (2, 3, 4, and 5 weeks). 
Although a gradual self-recovery was observed over time after the cessation of the 
BAK treatment and the 5-week BAK treated model resulted the most stable, the 
authors postulated that 2-4 week BAK treatment can successfully produce a 
satisfactory and applicable dry eye model (assessing the fluorescein scores and 
goblet cell density). On this basis, twice-daily topical administration of BAK (0.1%) 
for 15 days was used as an approach to induce dry eye in rabbits in this thesis, 
following the protocols previously described. The model was characterized by 
corneal fluorescein staining and CIC. The fluorescein dye stains the damaged 
epithelial cells or the disrupted intercellular junctions in the cornea.195,236,237 CIC, 
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on the other hand, is a technique whereby the superficial layers of the ocular 
surface are removed and evaluated; histological staining of CIC samples reveals 
the state and the number of the conjunctival epithelial cells and the goblet cells. 
During this study, both fluorescein and cytological scores increased significantly 
on day 7 and day 15 in BAK-treated eyes. The results demonstrated that twice-
daily topical administration of BAK at 0.1% for 15 days causes significant 
alterations on the ocular surface of rabbits that are indicative of dry eye disease, 
including corneal damage and alterations in the conjunctival epithelial and goblet 
cells. These findings are consistent with the findings obtained in the 
aforementioned studies using the same method and suggest that the 
experimental dry eye model can be used as a platform to evaluate the efficacy of 
artificial tears.  
The results obtained in the preliminary efficacy study of Formulation 3 in the 
experimental dry eye demonstrated a remarkable and statistically significant 
improvement in the ocular surface in as early as 7 days of the treatment 
(fluorescein and cytological scores decreased significantly compared with 
baseline). Corneal fluorescein staining results returned to normal in 7 days and the 
CIC results in 14 days. It should be noted that an improvement was observed on 
the ocular surface in the untreated control group as well; however, it was much 
slower, in agreement with the work of other authors.212 The scores of the two 
groups were significantly different on day 14 (for corneal fluorescein staining) and 
on day 21 (for both corneal fluorescein staining and CIC). These preliminary 
findings, indicative of the improvement of corneal damage and the return of the 
conjunctival epithelial and goblet cells to their normal state after treatment with 
the artificial tear formulation, suggest that the formulation may be beneficial in 
restoring the impaired ocular surface in DED.  
 A limitation of the study was the small number of animals used in the 
development of the experimental model of dry eye and in the subsequent 
preliminary efficacy study, which may have affected the power of the statistical 
 118 
analyses. Also, among the artificial tears developed, only Formulation 3 was 
tested. More comprehensive studies with larger sample sizes would be helpful to 
draw more conclusive results.  
In conclusion, the results obtained in this study demonstrated that the artificial 
tear formulations developed in this thesis present suitable properties for topical 
ophthalmic administration and that they are well-tolerated. With the 
incorporation of the in situ gelling polymer gellan gum, the artificial tears behave 
as in situ gelling systems, which could be beneficial in prolonging the ocular 
residence time of the formulations. Topical administration of BAK may be a useful 
method to induce dry eye in rabbits, and the experimental model of dry eye 
developed this way, in turn, could be a useful platform for the efficacy studies of 
artificial tear formulations. The preliminary efficacy study of the test formulation 
presents a proof of concept with promising preliminary results. Due to their 
potential of restoring the tear film and improving the ocular surface, the novel 
formulations developed in this thesis may be beneficial in the treatment of DED. 
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4. PRELIMINARY EFFICACY STUDIES 
ON DRY EYE UTILIZING THE ASTON 
BIOLOGICAL ANTERIOR EYE MODEL 
 
 
 
 
 
  
 120 
4.1. Introduction 
In dry eye research, various animal models have been developed to elucidate the 
complex pathophysiology of the disease and to investigate the efficacy of new dry 
eye therapies.173–188 While in vivo models constitute valuable tools in dry eye 
research, certain drawbacks such as high cost and time consumption, along with 
ethical considerations, have led to the exploration of alternative platforms.238,239  
In vitro and ex vivo ocular models, progressing with the advances in tissue 
engineering and biomedical technologies, have gained interest to provide reliable 
alternatives to the in vivo models.240–243 Compared with in vitro cell cultures that 
only provide partial information, ex vivo models possess the advantage of more 
closely reflecting the physiologic conditions and maintaining natural cell response. 
Furthermore, ocular surface ex vivo models offer the opportunity of tailoring 
several parameters such as blinking rate, temperature, and humidity, in order to 
induce and study dry eye at different severity levels and to investigate the effect 
of new dry eye treatments.220,221  
F. Menduni and Prof. J.S. Wolffsohn from the Ophthalmic Research Group of Aston 
University (Birmingham, UK) have developed a novel anterior eye model named 
the “Aston Biological Anterior Eye Model”.244 In the framework of the European 
Dry Eye Network “EDEN”, an optimization of the model and preliminary studies of 
the efficacy of the artificial tear formulations developed in this thesis were 
performed. The efficacies of the formulations were evaluated in terms of restoring 
and maintaining a healthy ocular surface in the physiologically active porcine eye 
model.  
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4.2. The Aston Biological Anterior Eye Model  
The Aston Biological Anterior Eye Model is a novel ex vivo complete anterior eye 
model that uses porcine eyes (Figure 4.1).244 In the model, porcine anterior 
segments are mounted in perfusion chambers and placed in a controlled system. 
The environmental control system is composed of a perfusion system and an 
irrigation system, designed to mimic tear replenishment and reproduce 
physiological conditions. The perfusion system supplies the endothelial back side 
of the mounted anterior segments with a physiological solution at controlled 
temperature, pressure, and flow rate; while the irrigation system hydrates the 
surface of the eye model at a controlled frequency. The model is placed in a 
laminar flow hood to avoid contamination. 
 
 
Figure 4.1. The Aston Biological Anterior Eye Model developed by Menduni and 
Wolffsohn.244 A: Perfusion chambers with mounted porcine anterior segments. B: 
perfusion system. C: irrigation system.  
 
 122 
4.2.1. Eyes 
Porcine eyes were enucleated from white domestic pigs (12-25 weeks old) after 
the animals were killed at a local abattoir (waste material) in Birmingham, UK. The 
enucleated eyes were transported to the laboratory at 4°C in Dulbecco’s Modified 
Eagle’s Medium (Lonza, Berkshire, UK) supplemented with 20% w/v dextran 
(Sigma Aldrich, UK), 10% Foetal Bovine Serum (Sigma-Aldrich, UK), 1% v/v L-
glutamine (Lonza, Berkshire, UK), 1% penicillin (10,000 units/ml; Sigma-Aldrich, 
UK) and streptomycin (10,000 mg/ml; Sigma-Aldrich, UK). The globes were 
dissected and mounted in the model immediately upon arrival.  
The porcine eyes used in the initial experiments were collected from animals that 
underwent scalding process at the abattoir (Figure 4.2.A). For a potentially better 
tissue quality, collection of eyes not subjected to scalding was arranged for later 
experiments (Figure 4.2.B).  
 
 
Figure 4.2. Enucleated porcine eyes. A: subjected to scalding process. B: not 
subjected to scalding process. 
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4.2.2. Chambers 
Enucleated eyes were mounted using the suction and the perfusion chambers 
(Figure 4.3) made of polytetrafluoroethylene (PTFE), the biologically and 
chemically inert and autoclavable material.  
 
Figure 4.3. Suction chamber (A) and perfusion chamber (B) made of PTFE. 
 
The surface aperture of the perfusion chamber was optimized to provide a larger 
area of exposure and facilitate access to conjunctiva in order to ensure optimal 
sampling in conjunctival impression cytology (CIC) assays (Figure 4.4).  
 
Figure 4.4. Perfusion chamber, before (A) and after (B) surface aperture 
optimization. 
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4.2.3. Mounting protocol 
The enucleated eyeball is located in the suction chamber with the ocular surface 
facing down. A mild vacuum is created through suction with a syringe to ensure 
that the eyeball stays firmly in position during dissection. Dissection is performed 
using a vibrating blade (PMF 220 CE, Bosch), separating and discarding the 
posterior segment while keeping the anterior segment in the chamber. The 
perfusion chamber is clamped securely onto the suction chamber and the suction 
chamber is displaced, leaving the mounted anterior segment in the perfusion 
chamber. The mounting procedure is illustrated in Figure 4.5.  
 
 
Figure 4.5. Mounting procedure. A: Enucleated eye. B: Placement of the eyeball in 
the suction chamber. C: Dissection with a vibrating blade. D: Clamping of the 
perfusion chamber. E: Release of the suction chamber. F: Mounted anterior 
segment.  
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4.2.4. Perfusion system 
Endothelial perfusion of the mounted anterior segments was achieved by passing 
a culture medium, heated to 37°C with a hot plate (SH-5H, MESE Ltd., Leeds, UK), 
through the perfusion chambers via a multichannel peristaltic pump (ISM597, 
Ismatec REGLO, Wertheim, Germany). Each perfusion chamber possessed a 
separate inlet, through which it received the perfusion medium, and a separate 
outlet, from which the medium was circulated back to the reservoir (Figure 4.6). 
The perfusion medium was composed of Dulbecco’s Modified Eagle’s Medium 
(Lonza, Berkshire, UK) supplemeted with 10% Foetal Bovine Serum (Sigma-Aldrich, 
UK), 1% v/v L-glutamine (Lonza, Berkshire, UK), 1% penicillin (10,000 units/ml; 
Sigma-Aldrich, UK) and streptomycin (10,000 mg/ml; Sigma-Aldrich, UK). The flow 
rate of the perfusion medium was adjusted to 1 ml/min for continuous supply to 
the anterior segment. The perfusion medium was replaced with a fresh one every 
24 hours when the model was run beyond 24 hours.  
 
 
Figure 4.6. Perfusion system. A: Perfusion medium. B: Hot plate. C: Multichannel 
peristaltic pump.  
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4.2.5. Irrigation system 
Epithelial irrigation of the mounted anterior segments was performed via an 
automated irrigation system, consisting of a spray unit and an electronic control 
unit (Figure 4.7). With the perfusion chambers placed vertically, the irrigation 
medium was sprayed onto the exposed surface of the eye model at set intervals 
in order to keep the epithelial surfaces hydrated, while simulating physiological 
conditions with repetitive tear replenishment and desiccation phases. The 
irrigation medium used in the system was the same as the perfusion medium. The 
system had a capacity of 4 spray bottles, allowing a maximum of 4 perfusion 
chambers with the mounted anterior segments to be used at once. 
 
 
Figure 4.7. Automated irrigation system; front and size views. A: Spray unit. B: 
Electronic control unit. 
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4.3. Dry eye model optimization 
Dry eye disease may arise due to reduced aqueous tear secretion or excessive tear 
evaporation, as described previously. Based on this fact, the dry eye state in the 
Aston Biological Anterior Eye Model was designed to be induced with a reduced 
irrigation frequency that simulates a decrease of the tear supplement to the 
surface of the eye and extend the recurring desiccation period.  
The irrigation frequency for “normal” conditions and “dry eye” conditions in the 
porcine eyes were selected thanks to the assessment of the tear film stability by 
non-invasive tear break-up time (NIBUT) measurements, using a tearscope 
(EASYTEAR®view+ All in One, Easytear, Italy). With this method, a grid pattern was 
reflected on the tear film and the distortion of the reflected pattern, indicative of 
the formation of dry spots on the tear film, was evaluated. 
Freshly enucleated porcine eyes (n=3) were mounted in the Aston Biological 
Anterior Eye Model and the grid pattern reflected on the corneas were videotaped 
after irrigation. Alterations in the reflected pattern and the time taken for their 
occurrence were evaluated. Representative images, extracted from the video at 
different time points, are illustrated in Figure 4.8.  
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Figure 4.8. Representative NIBUT images of a porcine eye after irrigation.  
 
As it can be seen from Figure 4.8, NIBUT measurements demonstrated that the 
tear film appears to lose its stability after 30 seconds. Based on this evaluation, an 
irrigation interval of 20 seconds for normal conditions and 40 seconds for dry eye 
conditions were selected. Also, corneal fluorescein staining and CIC were 
performed for the assessment of normal conditions and dry eye conditions, in eyes 
sprayed at relative selected frequencies.  
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Corneal fluorescein staining 
Corneal fluorescein staining was performed in freshly enucleated porcine eyes 
(baseline; n=4) subjected to scalding process at the abattoir, and after a 2-hour 
irrigation period in the Aston Biological Anterior Eye Model with either 20-second 
intervals (normal state; n=2) or 40-second intervals (dry eye state; n=2). For each 
measurement, fluorescein stain was applied to the eyes with sterile strips (Bio 
Fluoro strips impregnated with 1 mg of sodium fluorescein, Biotech Vision Care 
Pvt Lt., India) and the corneal staining was evaluated under blue illumination with 
a yellow filter (Aston fluorescein enhancement filter) after 2 minutes.  
No visible differences in corneal fluorescein staining were observed between the 
baseline, normal state, and dry eye state (Figure 4.9), which may be due to a 
possible tissue deterioration during the scalding process at the abattoir or during 
transportation/handling.  These findings suggest that corneal fluorescein staining 
may not be a suitable test for the ocular surface assessment of the enucleated 
porcine eyes, collected post-scalding and mounted in the model. 
 
 
Figure 4.9. Representative images of corneal fluorescein staining in porcine eyes. 
A: Freshly enucleated porcine eye (baseline). B: Porcine eye irrigated with 20-
second intervals for 2 hours (normal state). C: Porcine eye irrigated with 40-second 
intervals for 2 hours (dry eye state). No visible differences were observed between 
the baseline, normal state, and dry eye state.  
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Conjunctival impression cytology 
CIC was performed in freshly enucleated porcine eyes (baseline; n=4) subjected to 
scalding process at the abattoir, and after a 2-hour irrigation period in the Aston 
Biological Anterior Eye Model with either 20-second intervals (normal state; n=2) 
or 40-second intervals (dry eye state; n=2). The assay and the microscopic 
evaluation (Leica light microscope, Leica Microsystems, Germany) of the samples 
were performed as described in Section 3.2.7.1. For the histological staining in the 
assay, periodic acid, Schiff’s reagent, Papanicolaou’s solution 1b Hematoxylin 
solution S, xylene, and the mounting medium Entellan were purchased from 
Sigma-Aldrich (Dorset, UK), Supor 200 membrane disc filters from Pall 
Corporation (Michigan, USA), and ethanol absolute from Fisher Scientific 
(Loughborough, UK). 
Cytological scores and the corresponding Nelson grades of the model eyes at 
baseline (n=4), normal state (n=2), and dry eye state (n=2), obtained by the semi-
quantitative estimation of five cytological criteria as described in Section 3.2.7.1, 
are reported in Table 4.1.  
 
 Cytological score Nelson grade 
Baseline (n=4) 8.00 ± 0.82 2 
2h; 20s irrigation 
interval (n=2) 
7.50 ± 0.71 2 
2h; 40s irrigation 
interval (n=2) 
10.00 ± 2.83 3 
Table 4.1. Cytological scores and the corresponding Nelson grades obtained with 
different irrigation frequencies in the Aston Biological Anterior Eye Model. 
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The microscopic evaluation of CIC samples revealed alterations in the number and 
the state of conjunctival epithelial cells; whereas no goblet cells were observed. 
The freshly enucleated eyes demonstrated a Nelson grade of 2 already at baseline. 
The eyes irrigated every 20 seconds for 2 hours, to establish normal conditions, 
maintained the same Nelson grade as baseline; whereas an increase in the 
cytological score and the Nelson grade was observed in the eyes irrigated every 
40 seconds for 2 hours to establish dry eye conditions. Statistical analysis was not 
performed due to the small sample size. Representative CIC images are illustrated 
in Figure 4.10.  
These findings suggest that 20-second and 40-second irrigation intervals may be 
suitable to establish normal and dry eye conditions (respectively) in the Aston 
Biological Anterior Eye Model. Furthermore, CIC may be a useful assay for the 
ocular surface evaluation in the model. Further studies with an increased number 
of eyes would be necessary to obtain conclusive results. 
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Figure 4.10. Representative images of conjunctival impression cytology in porcine 
eyes. A: Freshly enucleated porcine eye (baseline). Nelson grade: 2. Epithelial cells 
(violet): large, mostly abnormally shaped, and moderate in number. Cell -cell 
contact: high. Nucleus/cytoplasm ratio: >1/5. Goblet cells: absent. B: Porcine eye 
irrigated with 20-second intervals for 2 hours (normal state). Nelson grade:2. 
Epithelial cells: smaller, and scarce to moderate in number. Cell -cell contact: 
moderate. Nucleus/cytoplasm ratio: 1/3–1/4. Goblet cells: absent. C: Porcine eye 
irrigated with 40-second intervals for 2 hours (dry eye state). Nelson grade:3. 
Epithelial cells: large, abnormally shaped, and scarce. Cell -cell contact: low. 
Nucleus/cytoplasm ratio: >1/5. Goblet cells: absent. Scale bars: 25 m. 
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4.4. Preliminary efficacy studies of the artificial 
tear formulations  
Preliminary efficacy studies of the artificial tear formulations developed in this 
thesis were performed in the Aston Biological Anterior Eye Model with CIC. Freshly 
enucleated porcine eyes (n=4), not subjected to scalding process, were mounted 
in the model and irrigated with the irrigation medium with 40-second intervals for 
2 hours, in order to establish dry eye conditions as previously described. 30 μL of 
Formulations 1a, 2a, and 3 were instilled in the model eyes (n=1 for each 
formulation) upon reaching dry eye conditions (at the end of 2 hours), and for a 
second time, 4 hours after the first instillation. One model eye was left untreated 
and used as control. The model eyes with the type of treatments they received 
during the study are illustrated in Figure 4.11. The irrigation frequency was kept 
constant and set to every 40 seconds to continue simulating dry eye conditions 
throughout the study.  
CIC was performed in freshly enucleated porcine eyes (baseline; n=4), after the 2-
hour irrigation period with 40-second intervals (dry eye state; t=0 of the 
treatment; n=4) and at 18 hours of the treatment (t=18h; n=1 for each formulation 
and the control) in the Aston Biological Anterior Eye Model. 
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Figure 4.11. Illustration of the model eyes with the corresponding treatments they 
received during the preliminary efficacy studies.  
 
Between the hours 4-18 of the treatment (overnight), the model was run 
unsupervised in the automated system. At hour 18, the spray bottles irrigating the 
eyes that received treatment with Formulations 1a and 2a were encountered in a 
rotated position, not providing the eyes with the irrigation medium. As the 
unintended cessation of the irrigation at an undetermined time point between the 
hours 4-18 caused excessive drying of the model eyes, the results relative to 
Formulations 1a and 2a were considered improper and are not included here.  
Cytological scores and the corresponding Nelson grades of the model eyes at 
baseline (n=4), dry eye state (n=4), and at 18 hours of the treatment (only for 
Formulation 3 and the control; n=1 for each), obtained by the semi-quantitative 
estimation of five cytological criteria as described in Section 3.2.7.1, are reported 
in Table 4.2.  
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 Cytological score Nelson grade 
Baseline (n=4) 8.25 ± 0.50 2 
Dry eye state; 0h (n=4) 10.25 ± 0.50 3 
Control at 18h (n=1) 10.00 3 
Formulation 3 at 18h (n=1) 4.00 1 
Table 4.2. Cytological scores and the corresponding Nelson grades in the Aston 
Biological Anterior Eye Model during preliminary efficacy studies.  
 
With two instillations of Formulation 3 in the model eye in dry eye state, an 
improvement in the cytological score and the Nelson grade was observed after 18 
hours; while the control eye maintained its grade. Statistical analysis was not 
performed due to the small sample size. Goblet cells, previously absent, were 
observed in the treated eye after 18 hours. Representative CIC images are 
illustrated in Figure 4.12. 
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Figure 4.12. Representative images of conjunctival impression cytology in the 
Aston Biological Anterior Eye Model during preliminary efficacy studies. A: Freshly 
enucleated porcine eye (baseline). Nelson Grade: 2. Epithelial cells (violet): large, 
mostly polygonal, and scarce to moderate in number. Cell -cell contact: low. 
Nucleus/cytoplasm ratio: varying from 1/3 to >1/5. Goblet cells: absent. B: Porcine 
eye irrigated with 40-second intervals for 2 hours (dry eye state; t=0 of the 
treatment). Nelson grade: 3. Epithelial cells: large, abnormally shaped, and scarce. 
Cell-cell contact: low. Nucleus/cytoplasm ratio: >1/5. Goblet cells: absent. C: 
Porcine eye treated with Formulation 3, t=18h. Nelson grade: 1. Epithelial cells: 
smaller and abundant. Cell-cell contact: high. Nucleus/cytoplasm ratio: 1/3–1/4. 
Goblet cells (pinkish-purple): poorly defined and moderate in number. D: Control 
eye, t=18h. Nelson grade: 3. Epithelial cells: large, abnormally shaped, and scarce 
to moderate in number. Cell-cell contact: moderate. Nucleus/cytoplasm ratio: >1/5. 
Goblet cells: absent. Scale bars: 25 m. 
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This preliminary study gives an insight into the use of Aston Biological Anterior Eye 
Model as a platform to study the effects of topical ophthalmic dry eye 
formulations, and into the efficacy of an artificial tear formulation developed in 
this thesis in improving the ocular surface in dry eye. The study had some 
limitations such as the small sample size and short duration, due to the technical 
problems related to the eye model; however, the preliminary results are 
promising. The findings suggest that the parameters of the Aston Biological 
Anterior Eye Model may be adjusted to mimic dry eye conditions and the platform 
may be a useful tool and a potential alternative to animal testing for the efficacy 
studies of artificial tear formulations. CIC findings related to Formulation 3 support 
the findings obtained in Chapter 3; suggesting that the artificial tear may be 
beneficial in improving the ocular surface in dry eye, with potential future 
application in the treatment of dry eye disease. Further experiments with a larger 
sample size/more repeats and longer duration are needed to obtain more 
conclusive results and establish the efficacy of the formulations. 
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5.1. Introduction 
Neutrophil extracellular traps (NETs) were described in 2004 as extracellular fibers 
of nuclear and granule components released by neutrophils, and were shown to 
disarm and kill bacteria.222 Over the past 15 years, NETs have attracted 
considerable attention; several aspects of these structures such as their 
morphology, components, and formation have been elucidated to an extent. 
Implications of NETs in health and disease continue to be explored.245 
Morphological changes such as loss of the multilobulated structure of the nucleus, 
chromatin decondensation, disintegration of nuclear and granular membranes,  
mixing of nuclear and cytoplasmic contents have been observed during NET 
formation, denominated NETosis.246,247 Extracellular DNA (eDNA), histones, and 
several proteins such as neutrophil elastase and myeloperoxidase have been 
identified as components of NETs.5,248 Different mechanisms have been described 
for NET formation, including suicidal (or lytic) NETosis, resulting in the death of the 
neutrophil releasing the NET material, and vital NETosis, where the neutrophil 
survives the process and remains viable.249 The cell death associated with NET 
formation is considered to be a new active cell death mechanism, different form 
apoptosis and necrosis.246  
Beside the defense against pathogens as part the innate immune system, NETs are 
considered to be involved in other physiological events such as coagulation and 
inflammatory processes.245,250 However, NET accumulation due to excessive 
production and/or impaired clearance may have negative effects; it has been 
associated with pathophysiological processes in autoimmune, autoinflammatory, 
and lung diseases, such as systemic lupus erythematosus, rheumatoid arthritis, 
diabetes, and cystic fibrosis.251,252 
While NETs may be involved in the defense against pathogens in healthy eye, 
excessive amounts of NETs and eDNA have been found on the ocular surface and 
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in the tear fluid of dry eye disease (DED) patients.5,6 Hyperosmolarity was shown 
to induce NET formation by neutrophils and postulated as a possible explanation 
of the elevated NET levels on the ocular surface of DED patients.28 Furthermore,  
tear nucleases that can degrade and clear eDNA from the ocular surface were 
shown to be deficient in severe DED patients, resulting in the accumulation of 
NETs in the tear film.5 The Tear Film and Ocular Surface Society Dry Eye WorkShop 
II that took place in 2017 with the participation of experts in dry eye field drew 
attention to the possible role of NETs in the pathogenesis of DED, emphasizing the 
need for further studies for better understanding the role of NETs in the disease 
and for the development of new therapeutic strategies.4 In fact, DNase I (a 
nuclease normally found in the tear fluid) eye drops are already being investigated 
as a new therapeutic approach in DED.6 
In the present thesis, a collaboration with the University of Birmingham, UK (with 
Prof. Graham Wallace from the Institute of Inflammation and Ageing at the 
University of Birmingham) was established to assess the effects of the artificial 
tear formulations developed in this thesis on NET formation. 
5.2. Ethics 
This study was performed at the research laboratories of the University of 
Birmingham in Queen Elizabeth Hospital Birmingham, UK, under existing ethics 
“Inflammation in Ocular Surface Disease” HRA rec. ref. 08/H1206/125, and with 
the written informed consent of the study volunteer. 
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5.3. Materials and methods 
5.3.1. Materials 
Dextran, Trypan blue solution, Triton™ X-100, phorbol 12-myristate 13-acetate, 
dimethyl sulfoxide (DMSO), and sodium chloride were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Phosphate buffered saline (PBS; Calbiochem®) was 
supplied by Merck KGaA (Darmstadt, Germany), Percoll® plus by GE Healthcare 
(Buckinghamshire, UK), and VectaMount® mounting medium by Vector 
Laboratories (Peterborough, UK). Roswell Park Memorial Institute medium (with 
L-glutamine; Gibco), paraformaldehyde (4% in PBS; Alfa Aesar), Sytox™ Green 
nucleic acid stain (Invitrogen), and glass microscope slides (“Superfrost Plus”, 
Thermo Scientific) were supplied by Thermo Fisher Scientific (Waltham, MA, USA). 
24-well culture plates (Costar®) were purchased from Corning (Corning, NY, USA), 
13 mm round glass cover slips from Paul Marienfeld GmbH & Co. KG (Lauda-
Königshofen, Germany), and heparinized vacutainer (Vacuette® tube) from 
Greiner Bio-One (Kremsmünster, Austria).   
5.3.2. Experimental procedure 
Neutrophils were isolated from the blood of a healthy volunteer, counted, and 
seeded into the wells of culture plates. Artificial tear formulations prepared in this 
thesis were incubated with unstimulated neutrophils, to determine whether they 
induce NETosis, and with neutrophils stimulated with the NETosis-inducing agent 
phorbol 12-myristate 13-acetate (PMA), to assess their effects on PMA-induced 
NETosis. 
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Isolation of neutrophils 
Neutrophils were isolated from human blood (collected the same day, in a 
heparinized vacutainer) with the following steps: 
- In a laminar flow hood (Labculture Plus, Esco Micro Pte. Ltd., Singapore), the 
blood sample was mixed with 2% dextran (in 0.9% NaCl solution) at a 
dextran:blood ratio of 1:6 and left for 40 minutes for the sedimentation of red 
blood cells. 
- The leukocyte rich plasma was removed from the dextran sedimentation, added 
dropwise to a Percoll gradient (2.5 mL of 72% and 5 mL of 50.4% Percoll in 0.9% 
NaCl), and centrifuged (Thermo Scientific Heraeus Megafuge 16, Thermo Fisher 
Scientific, Waltham, MA, USA) at 1100 rpm for 20 minutes.  
- The neutrophil layer was then collected from the gradient, added to a centrifuge 
tube containing 10 mL of Roswell Park Memorial Institute (RPMI) medium, and 
centrifuged at 1600 rpm for 10 minutes to obtain a pellet of neutrophils. The 
supernatant was discarded and the pellet was resuspended in 5 mL of RPMI by 
tapping and swirling gently. 
- Neutrophils were stained with Trypan blue (1:1) for live cells and counted with a 
haemocytometer (Improved Neubauer, Hawksley, Sussex, UK) under microscope 
(Zeiss Primo Star, Carl Zeiss AG, Oberkochen, Germany).  
NET visualization 
The artificial tear formulations were tested with unstimulated neutrophils and 
PMA-stimulated neutrophils. PMA was diluted in RPMI from a 1.6 mM stock 
solution (in DMSO) and had an in-well concentration of 25 nM.  
- In a laminar flow hood, 13 mm round glass cover slips were placed into the wells 
of 24-well culture plates. 2x105 neutrophils were seeded into each well in RPMI 
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(total volume was made up to 500 μL or 490 μL, for wells without and with PMA, 
respectively) and the culture plates were incubated in a CO2 controlled incubator 
(Thermo Scientific, Waltham, MA, USA) for 30 minutes at 37°C for neutrophil 
adherence to the cover slips.  
- 10 μL of the NETosis-stimulating agent PMA (2.5 μM) was added to the wells 
where NETosis stimulation was desired. 500 μL of each test formulation was added 
into their corresponding wells (3 wells without PMA and 3 wells with PMA for each 
formulation) and 500 μL of RPMI was added to the control wells (3 unstimulated 
controls and 3 PMA-stimulated controls), bringing the total volume in each well to 
1 mL. The culture plates were incubated in the incubator for 3 hours at 37°C.  
- The supernatant from each well was aspirated and discarded. The cover slips 
were covered with paraformaldehyde (4% in PBS; sufficient volume to cover the 
surface of the slips) and the culture plates were incubated in the incubator for a 
further 30 minutes at 37°C.  
- The samples were washed with PBS, permeabilized with Triton X-100, and 
stained with the nucleic acid stain Sytox green. These washes were performed 
using an apparatus adapted from Brinkmann et al.,253 made by placing and 
pressing parafilm strips over a test tube rack to create “craters” (Figure 5.1). A 
drop of each wash was placed into the craters. The cover slips were removed from 
the culture plates gently with tweezers, placed face-down onto the first wash and 
passed through the following washes:  
o PBS: 3 times for 5 minutes 
o Triton X-100 (0.1% in PBS): 1 minute 
o PBS: 5 minutes 
o Sytox green (1 μM in PBS): 5 minutes 
o PBS: 5 minutes 
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Figure 5.1. The apparatus used for washing and staining the samples in the NETosis 
study. The craters contain a drop of the washes.  
 
- The cover slips were mounted face-down onto microscope slides with the 
permanent mounting medium Vectamount and left overnight.  
- Samples were analyzed under fluorescence microscope (Leica DMI 6000B, Leica 
Microsystems, Wetzlar, Germany) at 400X magnification (excitation: 490 nm, 
emission: 523 nm). Three images were taken from different areas of each coverslip 
and the NETosis rate was calculated for each image as follows: 
NETosis rate (%) =
Number of neutrophils undergoing NETosis
Total number of neutrophils
 x 100 
The assessment was made according to the morphology of the stained nucleus 
and the nucleic acid content; loss of the multilobulated nuclear structure, nuclear 
swelling indicative of chromatin decondensation, and mixing of nuclear and 
cytoplasmic contents were accepted to be indicative of neutrophils undergoing 
NETosis, as demonstrated and recognized as such by previous studies.246,247 The 
cells were counted manually with ImageJ/FIJI software (Version 1.52i). The mean 
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NETosis rate was calculated for each specimen using the corresponding three 
images. 
5.3.3. Statistical analysis 
Statistical analyses were performed using the SPSS software (Version 24, Chicago, 
USA). The Kolmogorov-Smirnov test was performed to determine whether the 
data was normally distributed; the data showed a non-normal distribution. 
Therefore, the Mann-Whitney test was used for the comparisons of the NETosis 
rates. P-values were two-tailed and P<0.05 was considered to be statistically 
significant. 
5.4. Results 
NETosis rates of unstimulated neutrophils and neutrophils stimulated with the 
NETosis-inducing agent PMA, incubated with the artificial tear formulations, are 
reported in Table 5.1. 
 NETosis rate (%) 
 Unstimulated neutrophils 
PMA-stimulated 
neutrophils 
Control 34.74 ± 4.44 100.00 ± 0.00 
Formulation 1  21.75 ± 3.23 26.92 ± 10.12 
Formulation 1a 27.95 ± 9.46 31.15 ± 6.47 
Formulation 2 33.74 ± 13.14 49.73 ± 16.74 
Formulation 2a 26.94 ± 13.06 35.56 ± 14.72 
Formulation 3  30.37 ± 18.80 49.89 ± 28.03 
Table 5.1. NETosis rates of unstimulated and PMA-stimulated neutrophils incubated with 
the artificial tear formulations.  
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Unstimulated and untreated neutrophils (unstimulated control) had a NETosis 
rate of 34.74 ± 4.44% whereas PMA-stimulated untreated neutrophils (PMA-
stimulated control) had a NETosis rate of 100%. In unstimulated neutrophils 
(Figure 5.2A), no significant differences were found in NETosis rates between the 
control and the treatments (P>0.05), except for Formulation 1, which reduced the 
NETosis rate significantly (P<0.001).  
In PMA-stimulated neutrophils (Figure 5.2B), three-hour incubation with each of 
the artificial tear formulations significantly decreased the NETosis rates compared 
with the PMA-stimulated control (P<0.001), the greatest decrease being observed 
with Formulation 1. All of the formulations, except for Formulation 2, reduced the 
NETosis rates of the PMA-stimulated neutrophils to a degree that was not 
significantly different than the NETosis rate of the unstimulated control (P>0.05). 
Formulations 1 and 1a showed a higher efficiency compared with Formulation 2.  
Representative images of the PMA-stimulated neutrophils incubated with the 
artificial tear formulations, stained with the nucleic acid stain Sytox green, and 
visualized with fluorescence microscope, are illustrated in Figure 5.3.  
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Figure 5.2. NETosis rates of neutrophils after a three-hour incubation with the 
artificial tear formulations. A: In unstimulated neutrophils, no increase was 
observed in NETosis rates for any of the formulations compared with the control. B: 
All of the formulations significantly decreased the NETosis rates in PMA-stimulated 
neutrophils compared with the PMA-stimulated control.  
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Figure 5.3. Representative images of the PMA-stimulated neutrophils incubated 
with the artificial tear formulations. The samples were stained with the nucleic acid 
stain Sytox green and visualized with fluorescence microscope (magnification 
400X). Unstimulated control: Nuclei of the neutrophils are mostly multilobulated 
(arrow 1). PMA-stimulated control: Nuclei lost their multilobulated form; nuclear 
swelling (arrow 2), mixing of nuclear and cytoplasmic contents (arrow 3), and NETs 
(arrow 4) are visible. In PMA-stimulated neutrophils incubated with the artificial 
tear formulations, nuclei are mostly multilobulated, resembling the  unstimulated 
control. Scale bar: 25 µm.    
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5.5. Discussion 
NETs and their implications in health and disease have gained much interest since 
they were first identified in 2004. Excessive amounts of NETs have been found on 
the ocular surface of dry eye patients and linked to inflammation and the 
pathogenesis of DED.5,6 Therefore, decreasing NET formation on the ocular surface 
may be a useful new strategy in the treatment of DED. The aim of this study was 
to evaluate the effects of the formulations developed in this thesis on NET 
formation. With this purpose, the artificial tears were incubated with both 
unstimulated and PMA-stimulated neutrophils. 
The results obtained in this study demonstrated that the artificial tear 
formulations developed in this thesis did not cause a negative response in 
neutrophils that would manifest with increased NET formation. Furthermore, all 
of the five formulations decreased PMA-induced NETosis significantly after a 3-
hour incubation, with the most effective being Formulation 1, containing 
liposomes (phosphatidylcholine 2%), the bioadhesive polymer hydroxypropyl 
methylcellulose (0.5%), the osmoprotectant levocarnitine (0.1%), the antioxidants 
vitamin A (0.002%) and vitamin E (0.02%), fructose (1.8%), and borates (boric acid 
0.84% and sodium tetraborate anhydrous 0.08%). The present preliminary study 
was performed with neutrophils isolated from the blood of one healthy donor. 
Further studies with neutrophils obtained from different donors and with more 
repeats would help better establish the efficiency of the formulations in 
decreasing NET formation. It would also be interesting to test the formulation 
components individually. eDNA quantification as an indicator of the amount of 
NETs generated might also be a helpful additional technique in future studies. 
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6. GENERAL DISCUSSION 
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Dry eye disease (DED) is characterized by a loss of homeostasis of the tear film, 
where tear film instability and hyperosmolarity, and ocular surface inflammation 
and damage are involved.2 Re-establishing the homeostasis of the tear film and 
restoring the ocular surface are key in the treatment of the disease. Artificial tears 
are deemed first-line therapy for mild dry eye and may also be employed in more 
advanced stages of the disease in combination with other therapies.7 However, 
most of the commercially available artificial tears replace only the aqueous phase 
of the tear film and provide a symptomatic relief rather than restoring the tear 
film and treating the disease. Another shortcoming of such formulations is their 
short residence time on the ocular surface.8   
The objective of this doctoral thesis was to design and develop novel artificial tear 
formulations that effectively replenish the tear film and restore the ocular surface 
for the treatment of DED. With this purpose, five innovative artificial tear 
formulations with a range of components were designed and developed in this 
thesis. The novel formulations were characterized in terms of their 
physicochemical properties. For the formulations containing an in situ gelling 
agent, in situ gelling was simulated and rheological properties were evaluated. 
Tolerance of the five artificial tears was evaluated in vivo. The following steps were 
the development or optimization of new tools to evaluate the efficacy of the 
formulations and the subsequent preliminary efficacy studies. Finally, the effects 
of the artificial tears on NETosis, a recently popular phenomenon, were evaluated 
as a proof of concept.  
Design of novel artificial tear formulations 
A comprehensive literature review was conducted to gain knowledge of the 
advances in dry eye therapies and to select the formulation components. After a 
thorough investigation, novel artificial tears were designed to incorporate both 
aqueous and lipid components, taking into consideration key physicochemical 
characteristics. Different strategies were used to more closely resemble natural 
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tears, replenish both the aqueous-mucin and the lipid layer of the tear film, and 
ensure a prolonged ocular residence time. With this purpose, the formulations 
contained liposomes and/or a bioadhesive polymer (hydroxypropyl 
methylcellulose) and/or an in situ gelling polymer (gellan gum). The artificial tears 
were further enriched with components having antioxidant properties (vitamins 
A, C, and E), osmoprotectant properties (levocarnitine and trehalose), and 
antidessicant properties (trehalose) for an enhanced potential therapeutic 
efficacy in DED. 
Physicochemical characterization  
The novel artificial tear formulations were characterized in terms of pH, surface 
tension, viscosity, osmolarity, and liposome size, to ensure suitability for topical 
ophthalmic administration. The pH of the artificial tears was neutral to slightly 
alkaline (7.0–7.6), in an optimum pH range for ophthalmic preparations 
considering the very similar pH (7.0–7.5) and the buffering capacity of natural 
tears.79,80,82–84 The surface tension values of the formulations (44.6–48.7 mN/m) 
were within or slightly above the physiological range of natural tears (40–46 
mN/m)87 and the viscosity values (3.6–12.1 mPa.s) within the physiological range 
(1.0–8.3 mPa.s)17,93 or above the range without being excessively high. These 
features together would contribute to the uniform mixing of the artificial tears 
with natural tears and their proper spreading over the ocular surface, without 
compromising tear film stability or causing adverse effects such as visual 
disturbance and ocular discomfort.90 The formulations were slightly hypotonic 
(222.7–272.7 mOsm/L), constituting a favorable attribute considering the tear 
hyperosmolarity in DED patients.233,234 Moreover, the average sizes (191.0–200.1 
nm) and the unimodal size distribution exhibited by liposomes were suitable for 
an ophthalmic formulation. The results show that the artificial tear formulations 
demonstrate suitable physicochemical properties for topical ophthalmic 
administration. 
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Simulation of in situ gelling and rheological studies 
In order to simulate in situ gelling on the ocular surface, the artificial tears 
containing an in situ gelling agent (gellan gum at 0.25%; Formulations 2, 2a, and 
3) were mixed with simulated tear fluid (STF) at a proportion reflecting in situ 
conditions,226 and their rheological properties were evaluated. When mixed with 
STF, these formulations showed viscoelastic properties with elastic gel behavior. 
Furthermore, the gels demonstrated shear-thinning behavior and their dynamic 
viscosities at elevated shear rates (2.8–3.0 mPa.s; at 800–1100 s-1) were in the 
physiological range of natural tears. These rheological findings suggest that the 
gellan gum containing formulations can form viscoelastic gels with suitable 
viscosities upon ophthalmic administration and may extend the residence time of 
the formulations on the ocular surface.  
In vivo tolerance studies  
In vivo tolerance studies of the artificial tear formulations were performed in 
rabbits (n=6). The formulations were administrated every 30 minutes for 6 hours; 
the ocular surface and the clinical signs were evaluated macroscopically and 
graded over a 24-hour period, following a previously described protocol.227  The 
animals did not show any clinical signs or indicators of discomfort for any of the 
artificial tear formulations (grade 0) throughout the experiments, indicating that 
the formulations are well tolerated in rabbits.  
Development or optimization of new tools to evaluate the efficacy of 
artificial tears 
In dry eye research, preclinical research constitutes an important step for 
investigating the efficiency of new treatments. In this thesis, an in vivo dry eye 
model was developed as a platform to assess the efficacy of the artificial tear 
formulations. Dry eye was induced in rabbits (n=8) by twice daily topical 
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ophthalmic administration of the preservative benzalkonium chloride (BAK) at 
0.1% for 15 days.211,212 Corneal fluorescein staining and conjunctival impression 
cytology assays revealed significant changes on the ocular surface of the animals 
at the end of the BAK treatment, such as corneal damage, goblet cell loss, and 
alterations in conjunctival epithelial cells, which are encountered in DED. These 
findings suggest that the experimental dry eye model obtained with the topical 
administration of BAK could be a useful platform for the efficacy studies of new 
DED treatments.  
The author collaborated with researchers from Aston University to optimize a 
complete ex vivo anterior eye model developed at Aston University,244 for its 
utilization as an alternative tool for the efficacy studies. “Normal” conditions and 
“dry eye” conditions in the porcine eye model, called the Aston Biological Anterior 
Eye Model, were optimized by modifying the irrigation (with a tear analogue) 
frequency of the eyes. An irrigation interval of 20 seconds for normal conditions 
and 40 seconds for dry eye conditions were selected based on the assessment of 
non-invasive tear break-up time of porcine eyes and validated by conjunctival 
impression cytology. This ex vivo dry eye model, using waste material and offering 
the possibility of adjusting several environmental parameters as desired, may be 
a potential alternative to in vivo dry eye models. 
Preliminary efficacy studies 
Preliminary efficacy studies of Formulation 3, containing the in situ gelling agent 
gellan gum, the bioadhesive polymer hydroxypropyl methylcellulose, 
levocarnitine, vitamin C, trehalose, electrolytes and borates, were performed in 
vivo and ex vivo, in the previously described rabbit dry eye model and the Aston 
Biological Anterior Eye Model, respectively.  
In the rabbit dry eye model, the model eyes were treated with the test formulation 
three times a day for a period of 21 days (n=6 for the treatment group and n=2 for 
the control group). Significant improvements in the ocular surface was observed 
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in as early as 7 days of the treatment (significantly reduced fluorescein and 
cytological scores compared with baseline), with scores returning to normal levels 
in 7 days for corneal fluorescein staining and in 14 days for conjunctival impression 
cytology. These findings showing the repair of corneal damage, increase in goblet 
cell density, and the return of the conjunctival epithelium to its healthy state, 
indicate the restoration of the ocular surface with the formulation. An 
improvement in the ocular surface was observed in the control group as well, 
though much slower than in the treatment group. The difference between the two 
groups resulted significant on day 14 (for corneal fluorescein staining) and on day 
21 (for both assays). The study had some limitations such as the small sample size, 
which may have reduced the power of the statistical analysis. Also, due to the time 
limitation, only one of the artificial tears was tested. Nonetheless, the preliminary 
findings are promising and suggest that the novel artificial tear formulation 
developed in this thesis may be beneficial in restoring the ocular surface in dry 
eye, with potential future application in the treatment of DED. Further studies 
with larger sample sizes, which would allow for more potent statistical analysis, 
are needed to draw more concrete conclusions.  
In the ex vivo dry eye model, the efficacy of the artificial tear formulation in 
restoring the ocular surface of the physiologically active porcine eye model was 
assessed. With two instillations of Formulation 3 (at t=0 and t=4h), an 
improvement in the number and the state of the conjunctival epithelial cells was 
observed after 18 hours. Goblet cells, previously absent, were observed in the 
treated eye after 18 hours. In this preliminary study, statistical analysis was not 
performed due to the small sample size (n=1) for the treatment and the control. 
Preliminary conjunctival impression cytology findings obtained in this study 
support the findings obtained in the rabbit dry eye model. Further studies with a 
larger sample size/more repeats over a longer period of treatment would help 
obtain more conclusive results.  
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NETosis studies 
The possible involvement of neutrophil extracellular traps (NETs) in inflammation 
and DED pathogenesis has recently been emphasized.4,5 On this basis, the effects 
of the artificial tears on NET formation by unstimulated and stimulated 
neutrophils (undergoing NETosis) were assessed as a proof of concept, in 
collaboration with researchers from the University of Birmingham. In 
unstimulated neutrophils, the formulations did not cause an increase in NET 
formation compared with the untreated control. In neutrophils stimulated with 
the NETosis-inducing agent PMA, all of the five artificial tears reduced the 
formation of NETs significantly after a 3-hour incubation; the greatest reduction 
was observed with Formulation 1, containing liposomes (phosphatidylcholine 2%), 
the bioadhesive polymer hydroxypropyl methylcellulose (0.5%), the 
osmoprotectant levocarnitine (0.1%), the antioxidants vitamin A (0.002%) and 
vitamin E (0.02%), fructose (1.8%), and borates (boric acid 0.84% and sodium 
tetraborate anhydrous 0.08%). Testing the formulation components separately 
would be helpful in understanding the effects of the individual components on 
NETosis. This study was performed with neutrophils obtained from one healthy 
donor and constitutes a proof of concept. In light of the promising preliminary 
results, the artificial tears may be further investigated for their beneficial effects 
in decreasing NET formation in dry eye, where NETs are found in excessive 
amounts on the ocular surface.5,6 
Prospects for future research 
This doctoral thesis focused on the development of novel artificial tear 
formulations for the treatment of DED. With this purpose, five novel artificial tear 
formulations with suitable physicochemical properties and good in vivo tolerance 
(in rabbits) were developed in the thesis. Preliminary preclinical efficacy studies 
revealed promising results regarding the efficiency of the tested formulation in 
restoring an impaired ocular surface. Considerable reductive effects of the 
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formulations on NET formation were also observed in a preliminary study. 
Furthermore, the thesis provided insight into the feasibility and the potential use 
of an in vivo and a novel ex vivo dry eye model as a platform to evaluate the 
efficacy of new DED treatments.  
Prospects for future research include the establishment of the safety and efficacy 
of all of the five formulations with more comprehensive preclinical and clinical 
studies, for their potential future use in the treatment of DED. Moreover, the 
reductive effects of the formulations and the individual formulation components 
on NETosis can be further explored as an additional favorable quality in DED 
treatment. The present research can be further broadened by determination of 
the ocular residence time of the artificial tears with in vivo studies.  
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7. CONCLUSIONS 
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1. All of the five novel artificial tear formulations developed in this doctoral thesis, 
containing different combinations of liposomes (made up of phosphatidylcholine 
and cholesterol), a bioadhesive polymer (hydroxypropyl methylcellulose), an in 
situ gelling polymer (gellan gum), osmoprotectants (levocarnitine and trehalose), 
antioxidants (vitamins A, C, and E), and other formulation excipients (fructose, 
electrolytes, and borates), demonstrate suitable physicochemical properties for 
topical ophthalmic administration and are well tolerated in rabbits.  
2. Incorporation of gellan gum at 0.25% with electrolytes created artificial tears 
with in situ gelling properties, capable of producing viscoelastic gels that suggest 
an extended ocular residence time of the ophthalmic formulations. 
3. Twice-daily topical ophthalmic administration of the preservative benzalkonium 
chloride at 0.1% for 15 days induces significant alterations on the ocular surface 
of rabbits that are indicative of dry eye disease. In the conditions described in this 
thesis, the experimental dry eye model can be used as a platform to evaluate the 
efficacy of artificial tears.  
4. According to the preliminary efficacy study performed in the in vivo dry eye 
model, the novel artificial tear containing the in situ gelling polymer gellan gum 
(0.25%), the bioadhesive polymer hydroxypropyl methylcellulose (0.12%), the 
osmoprotectants levocarnitine (0.4%) and trehalose (1.68%), the antioxidant 
vitamin C (0.01%), borates (boric acid 0.84% and sodium tetraborate anhydrous  
0.08%), and electrolytes (sodium chloride 0.05% and potassium chloride 0.05%) 
may be beneficial in the treatment of dry eye disease. 
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8. CONCLUSIONES 
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1. Las cinco formulaciones de lágrimas artificiales desarrolladas en la presente 
tesis doctoral conteniendo diferentes combinaciones de liposomas (compuestos 
por fosfatidilcolina y colesterol), un polímero bioadhesivo 
(hidroxipropilmetilcelulosa), un polímero gelificante in situ (goma gelano), agentes 
osmoprotectores (levocarnitina y trehalosa), agentes antioxidantes (vitaminas A, 
C y E) y otros excipientes como fructosa, electrolitos y boratos presentaron unas 
propiedades fisicoquímicas que resultan adecuadas para la administración tópica 
oftálmica. Además, dichas formulaciones presentaron una tolerancia óptima in 
vivo (conejos).  
2. La incorporación de goma gelano a una concentración del 0,25% con electrolitos 
generó la formación de lágrimas artificiales con propiedades gelificantes in situ, 
capaces de producir geles viscoelásticos que sugieren un tiempo de residencia 
ocular prolongado para las formulaciones oftálmicas. 
3. La administración del conservante cloruro de benzalconio 0,1% dos veces al día 
durante 15 días induce alteraciones significantes en la superficie ocular de conejos 
que son indicativas de la enfermedad del ojo seco, incluyendo daño corneal, 
reducción de la densidad de células caliciformes y alteraciones en el epitelio 
conjuntival. El modelo experimental de ojo seco, en las condiciones ensayadas, 
puede ser empleado como plataforma para evaluar la eficacia de lágrimas 
artificiales. 
4. De acuerdo con los estudios preliminares de eficacia llevados a cabo en el 
modelo animal de ojo seco, la nueva lágrima artificial conteniendo el polímero 
gelificante in situ (goma gelano 0,25%), un polímero bioadhesivo como la 
hidroxipropilmetilcelulosa (0,12%), sustancias con actividad osmoprotectora 
(levocarnitina 0,4% y trehalosa 1,68%), el antioxidante vitamina C (0,01%), boratos 
(ácido bórico 0,84% y tetraborato de sodio anhidro 0,08%) y electrolitos (cloruro 
sódico 0,05% y cloruro potásico 0,05%), podría resultar beneficiosa en el 
tratamiento de la enfermedad de ojo seco.  
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